Unser Experte für Hepatitis C

Prof. Dr. med. Jörg Friedrich Schlaak

Spezialisierungen: Hepatitis C, Lebererkrankungen, Magen-Darm-Krankheiten, Endoskopie

Institution und Position: Chefarzt der Medizinischen Klinik I des Evangelischen Klinikums Niederrhein in Duisburg. APL-Professor an der Universität Duisburg-Essen.

Stand: 14.03.2018

Die Mitschrift des Interviews mit Prof. Dr. med. Jörg Friedrich Schlaak zum Thema “Hepatitis C”

Welche Ursachen für Leberentzündungen gibt es?

Ganz grob kann man drei große Ursachenblöcke unterscheiden, das ist einmal die Infektion mit Bakterien, Viren oder Parasiten, dann sind es die Autoimmunerkrankungen, und dann sind es Stoffwechseldefekte, entweder angeboren, oder Stoffwechseldefekte bedingt durch die Ernährung.

Welche Symptome sprechen für eine Leberentzündung?

Viele Lebererkrankungen verlaufen völlig asymptomatisch, d.h. ohne Symptome. Aber wenn ein Patient unter starker Müdigkeit und Abgeschlagenheit leidet oder wenn er Bauchwasser entwickelt oder Wasser in den Beinen, dann sind das oft Hinweise auf das Bestehen einer Lebererkrankung.

Welche Risikofaktoren begünstigen eine Leberentzündung?

Eine Leberentzündung kann durch viele Faktoren begünstigt werden. Grundsätzlich ist es so, dass wenn man an Übergewicht leidet oder zu viel Alkohol trinkt, eine Zusatzproblematik z.B. durch eine Virusinfektion dann deutlich schlimmer verläuft.

Wie gefährlich ist Alkohol für die Leber?

Alkohol ist grundsätzlich gefährlich für die Leber, wobei man hier die Menge beachten muss. Also für Frauen sind etwa 10gr, das entspricht zu einem halben Glas Weißwein und für Männer 20gr, das wäre so ein ganzes Glas Weißwein, gefährlich.

Welche Infektionswege für eine Hepatitis C sind häufig?

Der typische Infektionsweg für eine Hepatitis C ist über das Blut, das passiert z.B. durch Drogen oder früher auch durch Bluttransfusionen. Transfusionen heute sind sehr sicher. Geschlechtsverkehr als oft genannte Ursache, ist aber sehr selten.

Was sind die Unterschiede der Hepatitis C und Lebererkrankungen?

Die Hepatitis C verläuft chronisch im Gegensatz zu vielen anderen Lebererkrankungen, z.B. Hepatitis A oder Hepatitis E, die nur akut verlaufen. Das macht diese Erkrankung aber umso gefährlicher, weil sie dann eben zu Komplikationen führt.

Welche Leberwerte weisen auf eine akute/chronische Hepatitis C hin?

Wenn wir eine Hepatitis C diagnostizieren wollen, dann schaut sich der Arzt die sog. Transaminasen an. Auf dem Laborblatt steht dann GPT oder GOT, das sind die sog. Transaminasen, die weisen auf eine Entzündung der Leber, auf eine Hepatitis.

Wie gefährlich ist eine Hepatitis C?

Eine Hepatitis C kann zu einer chronischen Infektion führen in über 70% und die chronische Infektion, die chronische Entzündung der Leber führt dann zu einem Umbau, das nennen wir Leberzirrhose. Und als Komplikation der Leberzirrhose kann sich ein Leberkrebs entwickeln, beides sind sehr ernste Komplikationen.

Kann eine chronische Hepatitis C erfolgreich behandelt werden?

In den letzten Jahren haben wir deutliche Fortschritte in der Behandlung der chronischen Hepatitis C gemacht. Man muss sagen, dass mit den aktuellen Medikamenten Heilungsraten bis zu 100% zu erreichen sind. Also ein ganz erheblicher Fortschritt, der hier die letzten Jahren erreicht worden ist.

Welche Folgen hat eine chronische Leberentzündung?

Eine chronische Leberentzündung führt zum Leberumbau, das führt dann zur Leberzirrhose mit der Komplikation des Leberzellkrebses.

Woran erkennt man, dass man eine Leberzirrhose hat?

Die Leberzirrhose im Anfangsstadium macht sich oft nicht bemerkbar, aber im fortgeschrittenen Stadium hat man dann z.B. eine Gelbfärbung der Haut, eine Bauchwasseransammlung oder Wasser in den Beinen.

Wie gefährlich ist eine Leberzirrhose? Ist diese heilbar?

Die Leberzirrhose ist nur im Anfangsstadium oft heilbar, im fortgeschrittenen Stadium dann nicht mehr. Dann kommt oft für die Patienten nur noch eine Lebertransplantation in Frage.

Wie ist der Zusammenhang von Hepatitis C und Leberzellkrebs?

Die Hepatitis C führt zur Leberzirrhose und eine Komplikation vieler Leberzirrhosen ist dann die Entwicklung von Leberzellkrebs.

Kann Leberkrebs behandelt werden?

Ja, Leberkrebs kann behandelt werden. Leider kommen aber etwa 80% aller Patienten erst in einem Stadium zum Arzt, indem der Leberzellkrebs nicht mehr behandelbar ist, d.h. nicht mehr geheilt werden kann.

Wann muss eine Lebertransplantation ins Auge gefasst werden?

Die Lebertransplantation muss im Endstadium der Leberzirrhose ins Auge gefasst werden, d.h. wenn die Gelbfärbung der Haut eingetreten ist, Bauchwasser aufgetreten ist oder viel Wasser in den Beinen ist.

Ist Übergewicht ein Risiko für die Leber?

Die Fettlebererkrankung bedingt durch Übergewicht ist eine der bedeutendsten Ursachen mittlerweile geworden für Lebererkrankungen, so dass Übergewicht in Zusammenhang mit anderen Lebererkrankungen, z.B. eine Virushepatitis, unbedingt zu vermeiden ist, weil hier ein weiterer Risikofaktor dazu kommt.

Ich bin Suchtpatient mit Hepatitis C. Kann mir geholfen werden?

Auch für Suchtpatienten gibt es heute gute Heilungschancen, sie sprechen genauso gut an wie andere Patienten. Wichtig ist, dass die Suchterkrankung stabil behandelt ist, z.B. mit Polamidon oder Methadon, dann ist es kein Problem und die allermeisten dieser Patienten werden auch gesund.

Was gibt es Neues bei der Behandlung der Hepatitis C?

In den letzten Jahren hat es erhebliche Fortschritte bei der Medikamentenentwicklung gegeben und wir haben jetzt eine Vielzahl neuer Medikamente, die Heilungsraten zwischen 95-100% bieten, also hier ist eine ganz fantastische Entwicklung eingetreten.

Welche Innovationen erwarten Sie in den nächsten 3-5 Jahren?

Zusätzlich zu den bereits zugelassenen Medikamenten  werden in den nächsten Jahren auch weitere Medikamente zugelassen, die sicherlich ähnlich gut wirken werden, wie die aktuellen Medikamente, so dass, wenn ein aktuelles Medikament nicht anspricht, dann diese neuen Medikamente eingesetzt werden können.

Infos zur Klinik

Wir haben das gesamte Spektrum von Diagnosemöglichkeiten. Wir können also von der akuten Hepatitis bis hin zur Leberzirrhose alles diagnostizieren und auch behandeln. Wir arbeiten sehr eng auch mit einem Lebertransplantationszentrum zusammen, sodass wir alle Möglichkeiten haben in der Behandlung dieser Erkrankung.

Infos zur Person

Seit mehr als 25 Jahren befasse ich mich mit der Hepatitis C, mit der Betreuung von Patienten und ich habe auch wissenschaftlich sehr intensiv mich mit Hepatitis C befasst, viele Patienten behandelt und mich für die Therapie interessiert und die Wirkungsmechanismen.

Lebenslauf:

Prof. Dr. med. Jörg Friedrich Schlaak

Chefarzt der Medizinischen Klinik I des Evangelischen Klinikums Niederrhein in Duisburg, akademisches Lehrkrankenhaus der Heinrich-Heine-Universität Düsseldorf

Klinische Schwerpunkte:

Hepatologie, Gastroenterologie, Endoskopie, Infektiologie (chronische Virushepatitiden), HCC (Leberzellkarzinom)

Beruflicher Werdegang:

1982 Abitur, Gymnasium Kronshagen
1982 – 1988 Studium der Medizin, Christian Albrechts-Universität
Kiel
1989 Arzt im Praktikum in der Inneren Abteilung des
Kreiskrankenhauses des Kreises Plön in Preetz
1989 Promotion zum Doktor der Medizin in Kiel, Thema der
Dissertation: “Über die Wirkung verschiedener Überträgersubstanzen an der
Mesenterialarterie des Meerschweinchens” (magna cum laude)
1990 Arzt im Praktikum an der I. Medizinischen Klinik und
Poliklinik der Johannes Gutenberg Universität Mainz
1990 Approbation als Arzt und Beginn der Tätigkeit als
Assistenzarzt an der I. Med. Klinik und Poliklinik der Universität Mainz
1996 Facharzt für Innere Medizin
1998 Oberarzt der I. Med. Klinik und Poliklinik der
Universität Mainz
2000 Erwerb der Zusatzbezeichnung Gastroenterologie
2001 Oberarzt der Klinik für Gastroenterologie und
Hepatologie des Universitätsklinikums Essen (Direktor: Prof. Dr. med. G. Gerken)
2004 Stellvertretender Direktor der Klinik für
Gastroenterologie und Hepatologie des Universitätsklinikums Essen
seit 2013 Chefarzt der Medizinischen Klinik I des Evangelischen
Klinikums Niederrhein in Duisburg

Mitgliedschaften:

Publikationen:

Originalarbeiten
J. F. Schlaak, E. Hermann, M. Ringhoffer, P. Probst, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer
(1992): Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur.
J. Immunol. 22, 2771-2776. IF: 4,518
J. F. Schlaak, H. Löhr, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1993): Analysis of the in vitro
cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94, 168-
173. IF: 3,278
J. F. Schlaak, E. Hermann, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Differential effects of
IL-10 on proliferation and cytokine production of human γ/δ and α/β T cells. Scand. J. Immunol. 39, 209-215. IF:
1,882
J. F. Schlaak, E. Schmitt, C. Hüls, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): A sensitive and specific
bioassay for the detection of human interleukin-10. J. Immunol. Methods. 168, 49-54. IF: 2,005
J. F. Schlaak, P. Nieder, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Human T helper cells reactive with
somatic bacterial antigens belong to the Th1 subset. Med. Microbiol. Immunol. 183, 169-175. IF: 2,433
J. F. Schlaak, M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K.-H. Meyer zum Büschenfelde, B.
Fleischer (1994): T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102[2], 145-
149. IF: 6,372
H. F. Löhr, J. F. Schlaak, G. Gerken, B. Fleischer, H.-P. Dienes, K.-H. Meyer zum Büschenfelde (1994):
Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients
with chronic hepatitis of different etiology. Liver. 14, 161-166. IF: 4,412
C. Claus, J. F. Schlaak, M. Dittmayer, K.-H. Meyer zum Büschenfelde, W. Dippold. Inhibition of antibody-induced
proliferation of human CD8+ T cells by CD16+ natural killer cells (1994): Eur. J. Immunol. 24, 1208-1212. IF: 4,518
J. F. Schlaak, A. Schwarting, P. Knolle, K.-H. Meyer zum Büschenfelde, W. Mayet (1995): Effects of Th1 and Th2
cytokines on cytokine production and ICAM-1 expressionon synovial fibroblasts. Ann. Rheum. Dis. 54[7], 560-
565. IF: 8,727
J. F. Schlaak, C. Clauss, K.-H. Meyer zum Büschenfelde, W. Dippold (1995): Anti-GD3 antibodies are potent
activators of human γ/δ and α/β positive T cells. Scand. J. Immunol. 41[5], 474-480. IF: 1,882
P. Knolle, J. F. Schlaak, A. Uhrig, P. Kempf, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Human Kupffer
cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22[2], 226-229. IF: 10,401
H. F. Löhr, J. F. Schlaak, H. P. Dienes, J. Lorenz, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Liver
cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.
Digestion. 56[1], 41-45. IF: 2,032
M. Girndt, H. Köhler, E. Schiedhelm-Weick, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, B. Fleischer (1995):
Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune
defect in chronic hemodialysis patients. Kidney Int. 47[2], 559-565. IF: 8,520
H. F. Löhr, W. Weber, J. F. Schlaak, B. Goergen, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Proliferative
response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus
hepatitis B virus mutants. Hepatology. 22[1], 61-68. IF: 11,190
H. F. Löhr, J. F. Schlaak, G. Kollmannsperger, H.-P. Dienes, K.-H. Meyer zum Büschenfelde, G. Gerken (1996):
Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and
functional significance. Liver. 16, 174-182. IF: 4,412
J. F. Schlaak, I. Pfers, K.-H. Meyer zum Büschenfelde, E. Märker-Hermann (1996): Different cytokine profiles in
the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin.
Exp. Rheumatol. 14, 155-162. IF: 2,973
G. Zissel, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Regulation of cytokine release by alveolar
macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta. Eur. Cytokine Netw.
7[1], 59-66. IF : 1,800
M. Heike, J. F. Schlaak, H. Schulze-Bergkamen, S. Heyl, W. Herr, U. Schmitt, P. M. Schneider, K.-H. Meyer zum
Büschenfelde (1996): Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human
sarcoma: evidence for several recognized antigens. J. Immunol. 156[6], 2205-2213. IF: 5,362
A. Schwarting, J. F. Schlaak, J. Lotz, I. Pfers, K.-H. Meyer zum Büschenfelde, W. Mayet (1996): Endothelin-1
modulates the expression of adhesion molecules on synovial fibroblast-like synovial cell (FLS). Scand. J.
Rheumatol. 25, 246-256. IF: 2,607
G. Zissel, J. Homolka, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Anti-inflammatory cytokine release
by alveolar macrophages in pulmonary sarcoidosis. Am. J. Resp. Crit. Care Med. 154, 713-719. IF: 11,986
H. F. Löhr, J. F. Schlaak, A. W. Lohse, W. O. Böcher, M. Arenz, G. Gerken, K.-H. Meyer zum Büschenfelde
(1996): Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive
autoimmune hepatitis. Hepatology. 24, 1416-1421. IF: 11,190
M. Heike, J. F. Schlaak, S. Heyl, H. Schulze-Bergkamen, U. Schmitt, K.-H. Meyer zum Büschenfelde (1997):
Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells. Scand. J.
Immunol. 45[2], 221-226. IF: 1,882
A. Schwarting, J. F. Schlaak, E. Wandel, K.-H. Meyer zum Büschenfelde, W. Mayet (1997): Human renal tubular
epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol. Dial. Transplant. 12[5], 916-923.
IF: 3,488
J. F. Schlaak, M. Trippler, I. Ernst, K.-H. Meyer zum Büschenfelde, G. Gerken (1997): Chronic hepatitis C: The
viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy. J.
Hepatol. 27[5], 917-921. IF: 10,401
K. Barbulescu, C. Becker, J. F. Schlaak, E. Schmitt, K.-H. Meyer zum Büschenfelde (1998): Cutting edge: IL-12
and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4+ T
lymphocytes. J. Immunol. 160[8], 3642-3647. IF: 5,362
J. F. Schlaak, T. Pitz, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1998): IL-12 enhances deficient
HCV-antigen induced Th1-type immune response of peripheral blood mononuclear cells. J. Med. Virol. 56, 112-
117. IF: 2,217
H. F. Löhr, S. Krug, W. Herr, S. Weyer, J. F. Schlaak, T. Wölfel, G. Gerken, K.-H. Meyer zum Büschenfelde
(1998): Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic
hepatitis B. Liver. 18, 405-413. IF: 4,412
K. Hildner, E. Märker-Hermann, J. F. Schlaak, C. Becker, T. Germann, E. Schmitt, K.-H. Meyer zum
Büschenfelde, M. F. Neurath (1998): Azathioprine, mycophenolate mofetil and methotrexate specifically modulate
cytokine production by T cells. Ann. New York Acad. Sci. USA. 859, 204-207. IF: 3,155
M. F. Neurath, R. Wanitschke, M. Peters, K. Hildner, R. Tufan, K.-H. Meyer zum Büschenfelde, J. F. Schlaak
(1998). Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological
studies. Ann. New York Acad. Sci. USA. 859, 315-318. IF: 3,155
H. F. Löhr, G. Gerken, M. Roth, S. Weyer, J. F. Schlaak, K.-H. Meyer zum Büschenfelde (1998): The cellular
immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may
determine the therapy outcome. J. Hepatol. 29[4], 524-532. IF: 10,401
W. O. Böcher, S. Herzog-Hauff, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, H. F. Löhr (1999): Kinetics of
hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination:
stimulation of the in vitro antibody response by interferon gamma. Hepatology. 29[1], 238-244. IF: 11,190
M. F. Neurath, K. Hildner, C. Becker, J. F. Schlaak, K. Barbulescu, T. Germann, E. Schmitt, P. Schirmacher, S.
Haralambous, M. Pasparakis, G. Kollias, E. Märker-Hermann (1999): Methotrexate specifically modulates
cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for
methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115[1], 42-55. IF: 3,278
J. F. Schlaak, G. Tully, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): HBV-specific immune defect
in chronic hepatitis B is correlated with a dysregulation of pro- and antiinflammatory cytokines. Clin. Exp.
Immunol. 115, 508-514. IF: 3,278
M. F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (1999):
Randomised trial of mycophenolate mofetil for treatment of chronic active Crohn´s disease. Gut. 44[5], 625-628.
IF: 13,319
J. F. Schlaak, G. Tully, H. F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): The presence of high
amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBVinduced
immune response. J. Hepatol. 30, 353-358. IF: 10,401
K. Hildner, S. Finotto, C. Becker, J. F. Schlaak, P. Schirmacher, P. R. Galle, E. Märker-Hermann, M. F. Neurath
(1999): Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose
methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137-146. IF: 3,278
W. J. Mayet, A. Schwarting, A. P. Barreiros, J. F. Schlaak, M. F. Neurath (1999): Anti-PR-3 antibodies induce
endothelial IL-8 release. Eur. J. Clin. Invest. 29, 973-979. IF: 2,834
W. J. Mayet, E. Märker-Hermann, J. F. Schlaak, K.-H.Meyer zum Büschenfelde (1999): Irregular cytokine pattern
of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener’s granulomatosis. Scand.
J. Immunol. 49[6], 585-594. IF: 1,882
A. P. Barreiros, P. Schirmacher, R. Laufenberg-Feldmann, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (2000):
The early immune response in the liver of BALB/c mice infected with S. typhimurium. Scand. J. Immunol. 51[5],
472-478. IF: 1,882
T. Orth, M. Peters, J. F. Schlaak, F. Krummenauer, R. Wanitschke, W. J. Mayet, P. R. Galle, M. F. Neurath
(2000): Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month
pilot study. Am. J. Gastroenterol. 98[5]: 1201-1207. IF: 9,213
R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker,
D. Strand, J. Czaja, J. F. Schlaak, H. A. Lehr, F. Autschbach, G. Schurmann, N. Nishimoto, K. Yoshizaki, H. Ito,
T. Kishimoto, P. R. Galle, S. Rose-John, M. F. Neurath (2000): Blockade of interleukin 6 transsignaling
suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and
experimental colitis in vivo. Nat. Med. 6[5], 583-588. IF: 28,054
P. Micke, K. M. Beeh, J. F. Schlaak, R.Buhl (2001). Oral supplementation with whey proteins increases plasma
glutathione levels of HIV-infected patients. Eur. J. Clin. Invest 31[2], 171-178. IF: 2,834
B. Strobl, V. Arulampalam, H. Is’harc, S. J. Newman, J. F. Schlaak, D. Watling, A.P.Costa-Pereira, F. Schaper, I.
Behrmann, K. C. Sheehan, R. D. Schreiber, F. Horn, P. C. Heinrich, I. M. Kerr (2001). A completely foreign
receptor can mediate an interferon-gamma-like response. EMBO J. 20[19], 5431-5442. IF: 10,748
J.F. Schlaak, A.P. Barreiros, S. Pettersson, P. Schirmacher, K.H. Meyer zum Büschenfelde, M.F. Neurath (2001).
Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septic shock
induced by S. typhimurium in mice. Scand. J. Immunol. 54[4], 396-403. IF: 1,882
F. Aberger, A. P. Costa-Pereira, J. F. Schlaak, T. M. Williams, R. F. O’Shaughnessy, G. Hollaus, I. M. Kerr, A. M.
Frischauf (2001). Analysis of Gene Expression Using High-Density and IFN-gamma-Specific Low-Density cDNA
Arrays. Genomics 77[1/2], 50-57. IF: 2,793
J. F. Schlaak, C. Schramm, K. Radecke, K.-H. Meyer zum Büschenfelde, G. Gerken. Sustained suppression of
HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/Hepatitis C coinfection
(2002). J. Acquir. Immune. Defic. Syndr. 29[2], 145-148. IF: 4,425
A. P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is’harc, I. Gesualdo, S. J. Newman, I. M.
Kerr, V. Poli. Mutational switch of an IL-6 response to an interferon-gamma -like response (2002). P. Natl. Acad.
Sci. USA 99[12], 8043-8047. IF: 9,809
J.F. Schlaak, C.M.U. Hilkens, A.P. Costa-Pereira, B. Strobl, F. Aberger, A.M. Frischauf, I.M. Kerr (2002). Cell-type
and donor-specific transcriptional responses to interferon-alpha – use of customised gene arrays. J. Biol. Chem.
277[51], 49428-37. IF: 4,600
A.P. Barreiros, J.F. Schlaak, G. Gerken, P.R. Galle, H.F. Löhr. Interleukin-2 has no additional therapeutic efficacy
in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin
(2003). Eur. J. Clin. Invest. 33(7):628-9. IF: 2,834
L. Strahle, D. Garcin, P. Le Mercier, J.F. Schlaak, D. Kolakofsky. Sendai virus targets inflammatory responses, as
well as the interferon-induced antiviral state, in a multifaceted manner (2003). J. Virol. 77(14):7903-13. IF: 4,648
C.M.U. Hilkens, J.F. Schlaak, I.M. Kerr. Differential Responses to IFN-alpha Subtypes in Human T Cells and
Dendritic Cells (2003). J. Immunol. 171(10):5255-63. IF: 5,362
A. Luik, S. Knapp, M. Thursz, H.C. Thomas, J.F. Schlaak. Autoregulatory role of Interleukin-10 in hepatitis C
patients treated with IFN-± (2004). J. Interf. Cytok. Res. 24(10): 585-593. IF: 3,899
M. Jones, A. Davidson, L. Hibbert, P. Grünewald, J.F. Schlaak, S. Ball, G.R. Foster, M. Jacobs. Dengue virus
inhibits alpha interferon signaling by reducing STAT2 expression (2005). J. Virol. 79(9):5414-20. IF: 4,648
T. Zoepf, E.J. Maldonado-Lopez, P. Hilgard, A. Dechene, M. Malago, C.E. Broelsch, J. F. Schlaak, G. Gerken. Diagnosis of
biliary strictures after liver transplantation: Which is the best tool? (2005). World J. Gastroenterol. 11(19):2945-8.
IF: 2,433
S. Guan, H. Liu, D. Yang, M. Lu, M. Roggendorf, J. F. Schlaak. Establishment of a new low-density cDNA macroarray
and the application in the activity of IFN against HBV (2005). Chin J Exp Clin Virol. 19(3):236-9.
T. Zoepf, E. Maldonado-Lopez, P. Hilgard, J. F. Schlaak, M. Malago, C.E. Broelsch, U. Treichel, G. Gerken. Endoscopic
therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation (2005). Clin.
Gastroenterol. Hepatol. 3(11):1144-9. IF: 6,543
Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Quality of Life and Psychiatric Complications after Adult Living Donor Liver Transplantation (2006). Liver
Transpl., 12(12):1782-90. IF: 3,793
S. Guan, M. Lu, P. Grünewald, M. Roggendorf, G. Gerken, J. F. Schlaak. The interferon-alpha response in HBVtransfected
HepG2.2.15 cells is partially restored by lamivudine treatment (2007). World J. Gastroenterol., 13(2):
234-241. IF: 2,433
M. Bockhorn, A. Frilling, T. Benkö, J. Best, S.-Y. Sheu, M. Trippler, J. F. Schlaak, Broelsch CE. Tri-iodothyronine
as a stimulator of liver regeneration after partial and subtotal hepatectomy (2007). Eur. Surg. Res., 39(1):58-63.
IF: 1,431
M. Bockhorn, S. Schöllmann, B. Opitz, G.C. Sotiropoulos, S.-Y. Sheu, E. Niehues, M. Trippler, A. Frilling, C.E.
Broelsch, J. F. Schlaak. VEGF does not improve liver regeneration and survival after 90% subtotal liver resection
(2007), Hepatol. Res., 37(5):353-9. IF: 2,218
M. Bockhorn, M. Goralski, D. Prokofiev, P. Dammann, P. Grünewald, M. Trippler, M. Kamler, A. Frilling, C. E.
Broelsch, J. F. Schlaak. VEGF is important for early liver regeneration after partial hepatectomy (2007). J. Surg.
Res., 138(2):291-9. IF: 2,121
J. Wu, M. Lu, Z. Meng, M. Trippler, M. Roggendorf, G. Gerken, J. F. Schlaak. TLR-mediated control of HBV
replication by non-parenchymal liver cells in mice (2007). Hepatology, 46(6):1769-1778. IF: 11,190
M. Bockhorn, T. Benkö, B. Opitz, S.-Y. Sheu, G. C. Sotiropoulos, J. F. Schlaak, C. E. Broelsch, H. Lang. Impact of
hepatic vein deprivation on liver regeneration and function after major hepatectomy (2008). Langenbeck Arch.
Surg., 393(4):527-33. IF: 2,160
Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Selection of donors for adult living-donor liver donation: results of the assessment of the first 205 donor
candidates (2008). Psychosomatics, 49(2):143-51. IF: 1,669
R. Broering, J. Wu, Z. Meng, P. Hilgard, M. Lu, M. Trippler, A. Szczeponek, G. Gerken, J. F. Schlaak. TLR
stimulated non-parenchymal liver cells are potent suppressors of HCV replication (2008). J. Hepatol., 48(6):914-
22. IF: 10,401
M. Bockhorn, C. D. Fingas, Y. Gu, U. Rauen, E. Niehues, A. Frilling, C. E. Broelsch, J. F. Schlaak. Erythropoietin
improves liver regeneration and survival in rat models of extended liver resection and living donor liver
transplantation (2008). Transplantation, 86(11):1578-85. IF: 3,535
J.-P. Sowa, J. Best, T. Benko, M. Bockhorn, Y. Gu, A. Bucchi, G. Gerken, U. Rauen, J. F. Schlaak. The extent of
liver resection modulates the activation of transcription factors and the production cytokines that are involved in
liver regeneration (2008). World. J. Gastroenterol., 14(46):7093-100. IF: 2,433
Z. Meng, S. Qiu, X. Zhang, J. Wu, T. Schreiter, Y. Xu, D. Yang, M. Roggendorf, J. F. Schlaak, M. Lu. Inhibition of
woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene
expression (2009). Virology, 384(1):88-96. IF: 3,278
J. Wu, Z. Meng, J. Min, R. Pei, M. Trippler, R. Broering, A. Bucchi, J.-P. Sowa, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. HBV suppresses Toll-like receptor mediated innate immune
responses in murine parenchymal and non-parenchymal liver cells (2009). Hepatology, 49(4):1132-40. IF: 11,190
B. Wang, M. Trippler, M. Lu, R. Broering, G. Gerken, J. F. Schlaak. Toll-like receptor activated human and murine
hepatic stellate cells are potent regulators of hepatitis C virus replication (2009). J. Hepatol. 2009;51(6):1037-45.
IF: 10,401
X. Zhang, Z. Meng, S. Qiu, Y. Xu, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Lipopolysaccharide induced
innate immune responses in primary hepatocytes inhibit woodchuck hepatitis virus replication via interferonindependent
pathways (2009). Cell. Microbiol. 11(11):1624-37. IF: 4,816
M.R. Rani, Y. Xu, J. C. Lee, J. Shrock, A. Josyula, J. F. Schlaak, S. Chakraborthy, N. Ja, R.M. Ransohoff, R. A.
Rudick. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta (2009). Ann. N. Y. Acad.
Sci. 1182:58-68. IF: 3,155
J. Wu, Z. Meng, M. Jiang, E. Zhang, M. Trippler, R. Broering, A. Bucchi, F. Krux, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. TLR induced innate immune response in non-parenchymal liver
cells are cell type-specific (2010). Immunology. 129 (3), 363-374. IF: 3,735
Y. Erim, S. Tagay, M. Beckmann, S. Bein, V. Cicinatti, S. Beckebaum, W. Senf, J. F. Schlaak. Depression and
Protective Factors of Mental Health in People with Hepatitis C: a questionnaire survey (2010). Int. J. Nurs. Stud.
47(3):342-349. IF: 2,248
T. Benkö, S. Frede, Y. Gu, J. Best, H.A. Baba, J. F. Schlaak, H. de Groot, J. Fandrey, U. Rauen. Glycine
pretreatment ameliorates liver injury after partial hepatectomy in the rat (2010). J. Invest. Surg., 23(1):12-20. IF:
1,191
R. Broering, M. Trippler, M. Jiang, M. Lu, G. Gerken, J. F. Schlaak. The interferon stimulated gene 15 functions
as a proviral factor for the hepatitis C virus and as an attenuator of the IFN response in hepatocytes (2010). Gut,
59(8):1111-9. IF: 13,319
P. Burbelo, J. Kovacs, K. Ching, A. Issa, M. Iadarola, J. F. Schlaak, H. Masur, M. Polis, S. Kottilil. Proteome-wide
anti-HCV and anti-HIV antibody profiling for predicting and monitoring response to HCV treatment in HIV coinfected
patients (2010). J. Infect. Dis., 15;202(6):894-8. IF: 5,778
J. Ertle, A. Dechêne, J.-P. Sowa, V. Penndorf, K. Herzer, G. Kaiser, J. F. Schlaak, G. Gerken, W.-K. Syn, A.
Canbay. Nonalcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis (2011). Int. J.
Cancer. 1;128(10):2436-43. IF: 5,007
X. Zhang, Z. Ma, E. Zhang, M. Jiang, J. F. Schlaak, M. Roggendorf, M. Lu. Modulation of HBV replication and
hepatocyte differentiation by MicroRNA-1 (2011). Hepatology, 53(5):1476-85. IF: 11,190
A. Katsounas, M. Trippler, S. Bein, S. Kottilil, R. A. Lempicki, G. Gerken, J. F. Schlaak. Altered Expression of
SHIP, a Toll-like Receptor 2 and 4 Pathway Inhibitor, is Associated with the Severity of Liver Fibrosis in Chronic
Hepatitis C Virus Infection (2011). J. Infect. Dis., 204(8):1181-5. IF: 5,778
M. Montag, R. Broering, J. Min, M. Lu, J.-P. Sowa, G. Gerken, J. F. Schlaak. Corticosteroids shift the response
pattern of the hepatic innate immune system from an inflammatory to an anti-inflammatory state (2011). Int.
Immunol., 23(9):537-44. IF: 3,181
T.C. Lauenstein, T.A. Heusner, M. Hamami, J. Ertle, J. F. Schlaak, G. Gerken, A. Bockisch, G. Antoch.
Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries (2011). Rofo,
183(11):1058-1064. IF: 1,961
J. Wu, M.F. Chen, Y.C. Xia, Y. Guo, Y. Lin, C. Sun, C.Y. Zhang, Y. Chen, S.P. Liu, Y.H. Hao, M. Lu, J.F.
Schlaak., D.L. Yang. Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and
its control of HBV replication (2011). Chin. J. of Hepatol., 19(11):838-42.
A. Katsounas, M. Trippler, B. Wang, M. Polis, R. A. Lempicki, S. Kottilil, G. Gerken, J. F. Schlaak. CCL5 is a
marker for early fibrosis in chronic hepatitis C and is regulated by Toll-like receptor 3 signaling and interferon-±
therapy (2012). J. Viral Hep., 19(2):128-37. IF: 3,307
S. Naggie, A. Osinusi, A. Katsounas, E. Hermann, R. Lempicki, J.F. Schlaak, A. Thompson, P. Clark, M. Trippler,
K. Patel, B. Shivakumar, A. Muir, J. McHutchison, D. Goldstein, H. Masur, M. A. Polis, S. Kottilil. Dysregulation
Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With
Depressed Viral Kinetics And Therapeutic Response (2012). Hepatology. 56(2):444-54. IF: 11,190
A. Osinusi, S. Naggie, S. Poonia, M. Trippler, Z. Hu, J. F. Schlaak, D. Fishbein, H. Masur, M. Polis, S. Kottilil.
ITPA Gene Polymorphisms Significantly Affect Hemoglobin Decline and Treatment Outcomes in HIV/HCV Coinfected
Patients (2012). J. Med. Virol., 84(7):1106-14. IF: 2,217
A. Katsounas, M. Trippler, S. Kottilil, R. A. Lempicki, C. H. Lane, G. Gerken, J. F. Schlaak. Cytokine/Chemokine
patterns connect various host and viral characteristics with clinics during chronic hepatitis C (2012). Eur. J. Med.
Res., 11;17(1):9. IF: 1,398
J. Theysohn, J. F. Schlaak, S. Müller, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective internal
radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after Sorafenib
administration (2012). J. Vasc. Int. Radiol., 23(7):949-52. IF: 2,149
X. Zhang, Z. Ma, H. Liu, J. Liu, Z. Meng, R. Broering, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Role of Tolllike
receptor 2 in the immune response against Hepadnaviral infection (2012). J. Hepatol., 57(3):522-8. IF: 10,401
J. F. Schlaak, M. Trippler, Y. Erim, B. Kis, B. Wang, N. Scherbaum, G. Gerken. Common pathways in
endogenous depression and depression induced by IFN-± therapy for chronic hepatitis C (2012). PLoS One,
7(6):e38668. IF: 3,534
G. Ren, S. Esser, C. Jochum, J. F. Schlaak, G. Gerken, D. Schadendorf, U. Dittmer, G. Wu, Z. Yuan, J. Timm. IL21
augments the HBV-specific CD8+T cell response in vitro in patients coinfected with HIV-1 (2012). AIDS,
26(17):2145-53. IF: 6,557
J. M. Theysohn, S. Müller, J. F. Schlaak, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective
Internal Radiation Therapy (SIRT) of hepatic tumors: how to deal with the cystic artery (2012). Cardiovasc
Intervent Radiol., 36(4):1015-22. IF: 1,965
J. M. Ertle, D. Heider, M. Wichert, B. Keller, R. Kueper, P. Hilgard, G. Gerken, J. F. Schlaak. Combination of
Alphafetoprotein and Des-Gamma-Carboxy Prothrombin is superior in detection of Hepatocellular Carcinoma
(2013). Digestion, 87:121-131. IF: 2,032
A. Katsounas, J. J. Hubbard, C. H. Wang, X. Zhang, D. Dou, B. Shivakumar, S. Winter, J. F. Schlaak, R. A.
Lempicki, H. Masur, M. Polis, S. Kottilil, A. Osinusi. High Interferon Stimulated Gene ISG-15 Expression Affects
HCV Treatment Outcome in HIV/HCV Coinfected Patients (2013). J. Med. Virol., 85(6):959-63. IF: 2,217
M. Schuchmann, J.M. Kittner, J. F. Schlaak, D. Klass, N. Dikopolous, C. Eisenbach, T. Berg, C. Trautwein, R.
Günther, S. Zeuzem, R. Gösseringer, A. Ehrlich, K. Neumann, D. Wachtlin, M.F. Sprinzl, T. Zimmermann, W.O.
Böcher, P.R. Galle. Viral efficacy and safety of all-trans retinoic acid in HCV patients with previous non-response
(2013). Digest. Liver. Dis., 45(4):323-9. IF: 2,889
F. A. Tucci, R. Bröring, P. Johansson, J. F. Schlaak, R. Küppers. B cells in chronically hepatitis C virus-infected
individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes (2013). J. Virol.,
87(5):2956-62. IF: 4,648
D. A. Megger, T. Bracht, M. Kohl, M. Ahrens, F. Weber, A.-C. Hoffmann, C. Stephan, M. Eisenacher, J. F.
Schlaak, H. A. Baba, H. E. Meyer, B. Sitek. Combining different quantification techniques in proteomics-based
clinical studies reveals confident hepatocellular carcinoma biomarker candidates (2013). Mol. Cell. Proteomics,
12(7):2006-20. IF: 7,254
Kohl M, Megger DA, Trippler M, Meckel H, Ahrens M, Bracht T, Weber F, Hoffmann AC, Baba HA, Sitek B,
Schlaak JF, Meyer HE, Stephan C, Eisenacher M. A practical data processing workflow for multi – OMICS
projects (2013). Biochim Biophys Acta. doi:pii: S1570-9639(13)00092-7. 10.1016/j.bbapap.2013.02.029. IF: 3,191
I. Nel, H. A. Baba, J. Ertle, F. Weber, B. Sitek, M. Eisenacher, H. E. Meyer, J. F. Schlaak, A.-C. Hoffmann.
Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular
carcinoma (2013). Translat. Oncol., 6(4):420-8. IF: 2,558
R. Pei, B. Qin, X. Zhang, W. Zhu, T. Kemper, Z. Ma, M. Trippler, J. F. Schlaak, X. Chen, M. Lu. Interferon-induced
protein with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication (2013). J.
Innate Immun., in press. IF: 4,557
R. Broering, C. I. Real, K. Jahn-Hofmann, L. Ickenstein, M. John, M. Lutterbeck, K. Kleinehr, G. Gerken, J. F.
Schlaak. Chemical modifications on siRNAs avoid the Toll-like receptor-mediated activation of the hepatic
immune system in vivo and in vitro (2013). Int. Immunol., in press. IF: 3,181
R. Broering, M. Lutterbeck, K. Kleinehr, M. Trippler, L. Poggenpohl, A. Paul, G. Gerken, J. F. Schlaak. Longterm
stimulation of toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses
induced by poly I:C treatment (2013). J. Viral Hep., in press. IF: 3,307
M. Jiang, R. Broering, M. Trippler, L. Poggenpohl, G. Gerken, M. Lu, J. F. Schlaak. Toll-like receptor-mediated
immune responses are attenuated in the presence of the hepatitis B virus surface antigen (2013). J. Viral Hep., in
press. IF: 3,307
Z. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. Choi
criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for
hepatocellular carcinoma (2013). Oncol. Lett., 6: 1707-1712, 2013. IF: 0,987
C. Real, D. Megger, B. Sitek, K. Jahn-Hofmann, L. Ickenstein, M. John, K. Kuhlmann, M. Eisenacher, H. E.
Meyer, G. Gerken, R. Broering, J. F. Schlaak. Identification of Proteins that Mediate the Pro-viral Functions of the
Interferon Sensitive Gene 15 in Hepatitis C Virus Replication (2013). Antivir. Res., 100(3):654-61. IF: 3,434
Y. Gu, J.-P. Sowa, S. Zhang, A. Paul, G. Gerken, J. F. Schlaak. VEGF improves liver regeneration and survival
after 90% hepatectomy in a rat model of diet-induced steatosis (2013). Digestion, 22;88(4):235-242. IF: 2,032
Z. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. A new
model to estimate prognosis after Yttrium-90 radioembolization in patients with hepatocellular carcinoma (2013).
PLoS One, 8(12):e82225. doi: 10.1371/journal.pone.0082225. IF: 3,534
C. Hoyo-Becerra, A. Huebener, M. Trippler, M. Lutterbeck, Z. Liu, K. Truebner, T. Bajanowski, G. Gerken, D.M.
Hermann, J. F. Schlaak. Concomitant interferon alpha stimulation and TLR3 activation induces neuronal
expression of depression-related genes that are elevated in the brain of suicidal persons (2013). PLoS One,
8(12):e83149. IF: 3,534
P. Hilgard, A. Dechene, A. Canbay, K. Herzer, J. F. Schlaak, U. Treichel, A. Gassel, H. Baba, T. Zoepf.
Diagnostic Mini-Laparoscopy in hepatic diseases and primary liver- and bile duct cancer: An over 10-year
experience in 1788 cases (2014). Digestion, 89(2):156-164. IF: 2,032
J. Liu, M. Jiang, Z. Ma, K. Dietze, G. Zelinskyy, D. Yang, U. Dittmer, J. F. Schlaak, M. Roggendorf, M. Lu.
Stimulation of Mouse Liver Endothelial Cells by Toll-Like Receptor 1/2 Ligands shifts T cell suppression to antiviral
T cell immunity (2013). J. Immunol., 191(12):6178-90. IF: 5,362
J. Theysohn, J. Ertle, S. Müller, J. F. Schlaak, F. Nensa, S. Sipillae, A. Bockisch, T. C. Lauenstein. Hepatic
volume changes after lobar Selective Internal Radiation Therapy (SIRT) of hepatocellular carcinoma (2013). Clin.
Radiol. doi:pii: S0009-9260(13)00457-1. 10.1016/j.crad.2013.09.009. IF: 1,663
M. Jiang, R. Broering, M. Trippler, J. Wu, E. Zhang, X. Zhang, G. Gerken, M. Lu, J. F. Schlaak. MicroRNA-155
controls toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver (2014). J. Viral Hep.,
21(2):99-110. IF: 3,307
J. Schelhorn, J. Theysohn, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal
Radiation Therapy of Hepatic Tumors: is coiling of the gastroduodenal artery always beneficial (2014)? Clin.
Radiol., in press. IF: 1,663
A. Baraniskin, S. Nöpel-Dünnebacke, C. Gerges, T. Bracht, B. Sitek, H. E. Meyer, J. F. Schlaak, J. Ertle, R.
Schroers, C. Pox, W. Schmiegel, S. A. Hahn. Analysis of U2 small nuclear RNA fragments in the bile
differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders (2014).
Dig. Dis. Sci., in press. IF: 2,550
F. A. Tucci, R. Broering, M. Lutterbeck, J. F. Schlaak, R. Küppers. Intrahepatic B cell follicles of chronically
hepatitis C virus-infected individuals lack signs of an ectopic germinal center reaction (2014). Eur. J. Immunol., in
press. IF: 4,518
A. Katsounas, J. J. Rasimas, M. A. Polis, G. Guido, J. F Schlaak, R. A Lempicki, D. L. Rosenstein, S. Kottilil.
Interferon Stimulated Gene ISG20 links psychiatric events to distinct Hepatitis C Virus responses in HIV patients
(2014). J. Med. Virol., IF: 2,217
C. Thöns, C. Berger, M. Trippler, H. Siemann, M. Lutterbeck, R. Bröring, J. F. Schlaak, F. M. Heinemann, P.A.
Horn, J. Nattermann, N. Scherbaum, G. Alter, J. Timm. KIR2DL3+NKG2A- Natural Killer Cells are Associated with
Protection from Productive Hepatitis C Virus Infection in People who Inject Drugs (2014). J. Hepatol., IF: 10,401.
J. Wu, M. Chen, Y. Lin, Y. Xia, C. Sun, J. Wang, Y. Guo, J. Song, E. Zhang, B. Wang, X. Zhen, J. F. Schlaak, M.
Lu, D. Yang. Polyinosinic-polycytidylic acid treatment leads to the Interferon-dependent clearance of hepatitis B
virus in a hydrodynamic injection mouse model (2014). J. Virol., IF: 4,648
El Fouly, J. Ertle, A. El Dorry, M. Shaker, H. Abdella, S. Mueller, E. Barakat, T. Lauenstein, A. Bockisch, G.
Gerken, J. F. Schlaak. Intermediate Stage Hepatocellular Carcinoma: Radioembolization with Yttrium 90 or
Chemoembolization (2014)? Liver Int., 4,412.
J. Padden, D. A. Megger, T. Bracht, H. Reis, M. Kohl, M. Eisenacher, J. F. Schlaak, A. E. Canbay, F. Weber, A.-
C. Hoffmann, K. Kuhlmann, H. E. Meyer, H. A. Baba, B. Sitek. Identification of novel biomarker candidates for the
immunohistochemical diagnosis of cholangiocellular carcinoma (2014). Mol. Cell. Proteomics, in press. IF: 7,254
C. Hoyo-Becerra, Z. Liu, J. Yao, B. Kaltwasser, D. M. Hermann, J. F. Schlaak. Rapid regulation of depressionassociated
genes in a new mouse model mimicking interferon-±-related depression in hepatitis C virus infection
(2014). Mol. Neurobiol., in press. IF: 5,286
I. Nel, H.A. Baba, F. Weber, B. Sitek, M. Eisenacher, H.E. Meyer, J.F. Schlaak, A.C. Hoffmann. IGFBP1 in
epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular
carcinoma (2014). Biomark Med. 8(5):687-98. IF: 2,858
J. Schelhorn, T. Schlosser, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal
Radiation Therapy of Hepatic Tumors: Procedural implications of a patent hepatic falciform artery (2014).
Springerplus. 3:595.
H. Reis, C. Pütter, D. A. Megger, T. Bracht, F. Weber, A.-C. Hoffmann, J. Wohlschlaeger, S. Hagemann, M.
Eisenacher, A. Scherag, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. A structured proteomic
approach identifies 14-3-3Sigma as a novel and reliable diagnostic protein biomarker in liver tumours. BBA – Prot.
Proteom., in press. IF: 3,191
Z. Zhang, J. Xia, B. Sun, Y. Dai, X. Li, J. F. Schlaak, M. Lu. In vitro and in vivo replication of a chemically
synthesized consensus genome of hepatitis B virus genotype B (2015). J Virol Methods. pii: 213:57-64. IF: 1,883
T. Bracht, V. Schweinsberg, M. Trippler, M. Kohl, M. Ahrens, J. Padden, W. Naboulsi, D. A. Megger, M.
Eisenacher, C. H. Borchers, J. F. Schlaak, C.-A. Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B. Sitek.
Quantitative proteomics reveal the expression of fibulin-5 in association with hepatic fibrosis (2015). J. Proteome
Res., in press.
H. Reis, J. Padden, M. Ahrens, C. Pütter, S. Bertram, L. Pott, A.-C. Reis, F. Weber, B. Juntermanns, A.-C.
Hoffmann, M. Eisenacher, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. Differential proteomic and
tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid
carcinomas. Pathology, in press.
Eingereichte Publikationen:
M. A. Guzzardi, N. Habib, D. Kitsberg, K. Uygun, M. Trippler, J. F. Schlaak, J. Timm, N. Friedman, Y. Nahmi.
Transcriptional-Metabolic Reprogramming of HCV-infection from Primary Human Hepatocytes Co-cultures to
Clinical Samples. Submitted.
S. Hagemann, H. Reis, K. Lorenz, J. Wohlschlaeger, D. Moellmann, B. Sitek, J. F. Schlaak, H. E. Meyer, M.
Eisenacher, D. A. Megger, A.-C. Hoffmann, F. Weber, H. A. Baba. Eukaryotic elongation factor 2 is a
prognostic marker and its kinase activated in hepatocellular carcinoma eEF2 and eEF2-kinase in HCC.
Submitted.
Z. Zhang, Y. Zhang, Q. Su, L. Zhang, J. F. Schlaak, M. Lu, X. Li. Family-based association testing reveals
different roles of IL28B, TLR3, and HLA-DR in hepatitis B virus infection. Submitted.
R. Broering, M. Trippler, M. Lutterbeck, C.I. Real, D.A. Megger, T. Bracht, B. Sitek, K. Kuhlmann, M.
Eisenacher, H.E. Meyer, H.A. Baba, F. Weber, A.C. Hoffmann, G. Gerken, J. F. Schlaak. Proteasome
S. Berhane, H. Toyoda, T. Tada, T. Kumada, C. Kagebayashi, S. Satomura, N. Schweitzer, A. Vogel, M.
P.Manns, J. Benckert, T. Berg, J. Best, A. Dechêne, G. Gerken, J. F Schlaak, A. Weinmann, M. A. Wörns, W.
Yeo, F. Mo, S. L.Chan, H. Reeves, P. Johnson. Serology-based diagnosis and prognostication in HCC:
Application of the GALAD and BALAD-2 models in an international setting. Submitted.
J. Petersen, R. Heyne, S. Mauss, J. F. Schlaak, W. Schiffelholz, C. Eisenbach, H. Hartmann, M. Wiese, K.
Boeker, H.-F. Loehr, C. John, M. Leuschner, C. Trautwein, G. Felten, A. Trein, W. Krause, S. Ruppert, T.
Warger, D. Hueppe. Efficacy and safety of tenofovir disoproxil fumarate treatment in chronic hepatitis B
patients: a 3 year prospective field practice study in Germany. Submitted.
D. A. Megger, K. Rosowski, M. Ahrens, T. Bracht, M. Eisenacher, J. F. Schlaak, F. Weber, A.-C. Hoffmann,
H. E. Meyer, H. A. Baba, B. Sitek. Quantitative proteome analysis of human hepatocellular carcinoma using
tandem mass tags. Submitted.
W. Naboulsi, D. A. Megger, T. Bracht, M. Kohl, M. Turewicz, M. Eisenacher, D. M. Voss, J. F. Schlaak, A.-C.
Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B Sitek. Quantitative proteome analysis of hepatocellular
carcinoma tissue reveals Versican as potential biomarker for early-stage HCC diagnosis. Submitted.
C. I. Real, M. Lu, J. Liu, X. Huang, M. Trippler, M. Hossbach, J. Deckert, K. Jahn-Hofmann, L. M. Ickenstein,
M. J. John, K. Gibbert, U. Dittmer, H.-P. Vornlocher, R. Schirmbeck, G. Gerken, J. F. Schlaak, R. Broering.
The hepatitis B virus (HBV) surface antigen impedes hepadnaviral replicationdependent interferon responses
in a HBV transgenic mouse model. Submitted.
S. Bertram, J. Padden, J. Kaelsch, M. Ahrens, L. Pott, A. Canbay, F. Weber, C. Fingas, A. C Hoffmann, A.
Vietor, J. F Schlaak, M. Eisenacher, H. Reis, B. Sitek, H. A Baba. Immunostaining for SerpinH1, 14-3-3-
Sigma and ki67 may be useful to differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Submitted.
Fallmitteilungen
T. Wölfel, P. Schirmacher, J. F. Schlaak, P. Knolle, H.-P. Dienes, W. Dippold, K.-H. Meyer zum Büschenfelde, G.
Gerken. Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and
advanced human immunodeficiency virus infection (1994). Clin. Investig. 72, 1030-1036.
C. Schramm, J.F. Schlaak, P.R. Galle. Rapid development of Epstein-Barr virus-associated Hodgkin’s disease
after cessation of foscarnet therapy in an HIV-infected patient (2000). Int.J.STD AIDS 11[9], 609-610.
G.C. Sotiropoulos, J. Treckmann, A. Radtke, G. Antoch, E. Brokalaki, J.F. Schlaak, C. E. Broelsch. Arterioportal fistula
complicating endoscopic retrograde cholangiography (2005). Endoscopy 37[1], 93-4.
A. Katsounas, C. Jochum, A. Canbay, J.F. Schlaak, W. Gerlich, G. Gerken. Core Promoter Mutant HBV Non-responding
To Adefovir after Viral Breakthrough on Lamivudine: Rapid Virologic Response to Tenofovir Plus Lamivudine in a
Cirrhotic Patient (2008). Eur J Med Res. 27;13(10):472-5.
A. Abendroth, R. Klein, J.F. Schlaak, K.A. Metz, G.J. Dobos, J. Langhorst. Imposanter Befund einer Melanosis coli
nach jahrzehntelangem Abusus von Anthrachinonderivaten – Ein Risikofaktor für kolorektale Neoplasien (2009)?
Z. Gastroent. 47 (6), 579-82.
M. Buechter, C. G. Klein, C. Kloeters, J.F. Schlaak, A. Canbay, G. Gerken, A. Kahraman. Tacrolimus as a
reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with
IgG4-associated cholangitis (2014). Z Gastroenterol. 52(6):564-568.
Übersichtsarbeiten
P. Knolle, H. Löhr, U. Treichel, H.-P. Dienes, A. Lohse, J. F. Schlaak, G.Gerken (1995): Parenchymal and
nonparenchymal liver cells and their interaction in the local immune response. Z. f. Gastroenterol., 33, 613-
620.
J. F. Schlaak, H. Koehler, G.Gerken (1996): Hepatitis G virus: an old, but newly discovered hepatotropic
virus. Is it of interest for the nephrologist ?. Nephrol.Dial.Transplant. 11[8], 1522-1523.
J. F. Schlaak, G. Gerken (1997): Aktuelle Strategie in der Diagnostik und Therapie der chronischen
Virushepatitiden. Tägl. prax., 38, 515-526.
J. F. Schlaak, G. Gerken (1997): Diagnose und Therapie der chronischen Virushepatitiden. Internist. prax.,
37, 519-530.
J. F. Schlaak (1997): Virushepatitiden – Verlauf und extrahepatische Manifestationen. Krankenhaus Arzt, 70,
8-9.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnostik und Therapie. Fortschr.
Med.115:34-36.
J. F. Schlaak, G. Gerken (1997): G. Chronische Hepatitiden. Differentialdiagnose der Hepatitis C. Fortschr.
Med.115:38-39.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnose der Hepatitis B, D und G.
Fortschr. Med.115:44-46.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Diagnose der autoimmunen Lebererkrankungen.
Fortschr. Med. 115:33-34.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der chronischen Virushepatitiden.
Fortschr. Med. 115:48-50.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der autoimmunen Leberkrankungen.
Fortschr. Med. 115:52-53.
J. Wu, R. Bröring, J. F. Schlaak. The role of the innate immune system of the liver in the control of HBV and
HCV (2008). Virologica Sinica 23 (2): 116-123.
J. Ertle, T. Lauenstein, J. F. Schlaak. Benefit of using TARE-Y90 comparing with TACE in the management
of primary and secondary liver tumors (2011). Eur. J. Clin. Med. Oncol., 3(1): 44-50.
A. Katsounas, J. F. Schlaak, R. A. Lempicki. CCL5: A Double-edged Sword in Host Defense against the
Hepatitis C Virus (2011). Int. Rev. Immunol., 30(5-6):366-78. IF: 2,641
R. Broering, M. Lu, J. F. Schlaak. Toll-like receptors in liver health and disease: mechanisms and therapeutic
potential (2011). Clin. Science, 1;121(10):415-26. IF: 4,613
X. Zhang, A. Kraft, R. Broering, J. F. Schlaak, U. Dittmer, M. Lu. Preclinical development of TLR ligands as
drugs for the treatment of chronic viral infections (2012). Exp. Opin. Curr. Drug Disc., 7(7):597-611.
J. Ertle, G. Gerken, J. F. Schlaak. Lokalablative Therapien zur Behandlung des hepatozellulären Karzinoms
(2012). Der Gastroenterologe, in press.
J. Ertle, G. Gerken, J. F. Schlaak. Radioembolisation bei forgeschrittenem hepatozellulären Karzinom.
Viszeralmedizin (2012). Viszeralmed. 28(5), 311-16.
K. Gibbert, J. F. Schlaak, D. L. Yang, U. Dittmer. Interferon alpha subtypes: Distinct Biological activities in
anti-viral therapy (2012). Br. J. Pharm., 168(5):1048-58.
H. Lang, J. Ricke, J.F. Schlaak. Resektion oder interventionelle Therapie beim hepatozellulären Karzinom:
welche Methode für welchen Patienten (2013)? Dtsch Med Wochenschr. 138(36):1780-4.
J. F. Schlaak. Zufallsbefund Leberrundherd: Bösartig oder gutartig (2013)? Der Allgemeinarzt, 11:34-38.
J. F. Schlaak. Labordiagnostik bei primärem Leberzellkarzinom (2014). Der Gastroenterologe, 9:138-144.
I. Nel, P. David, G. Gerken, J. F. Schlaak, A.-C. Hoffmann. Role of circulating tumor cells and cancer stem
cells in hepatocellular carcinoma (2014). Hepatol. Int., 8(3):321-9.
C. Hoyo-Becerra, J. F. Schlaak, D. M. Hermann. Insights from interferon-alpha-related depression for
idiopathic major depression (2014). Brain Behav. Immun., 42:222-31.
J. F. Schlaak. Radioembolisation with yttrium-90 glass microspheres for patients with hepatocellular
carcinoma: a review (2014). Hep. Oncol., 1(4): 387-393.
J. F. Schlaak. The evolving role of radioembolization for the treatment of Hepatocellular carcinoma.
(Submitted)
Buchbeiträge
J. F. Schlaak, G. Gerken (1997): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
J. F. Schlaak, G. Gerken (2001): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
J. F. Schlaak, G. Gerken (2003): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion.
In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
J. F. Schlaak, G. Gerken (2004): Management of IL-2 toxicity. In: Immunotreatment and gene therapy of HIV
infection, Hengge, Kabelitz (Hrsg.), Unimed Verlag, Bremen.
A. Canbay, J. F. Schlaak, G. Gerken, R. Gieseler (2007). Dysregulated Apoptosis in Liver Diseases. In : Cell
apoptosis: Regulation and environmental factors, (Schultz (Hrsg.), Nova Science Publishers, Inc, New York,
USA.
J. F. Schlaak, G. Gerken (2007): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion.
In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
C. Jochum, J.F. Schlaak (2010). Hepatitis C: Symptoms, Diagnosis and Treatment, pp. 135-158 In :
Advances in Medicine and Biology, Vol. 9, (Berhardt (Hrsg.), Nova Science Publishers, Inc, New York, USA.
R. Bröring, M. Lu, J.F. Schlaak (2011). Toll like receptors in chronic viral hepatitis – friend and foe. In: Viral
Hepatitis, ISBN 979-953-307-103-8, InTech, Rijeka, Croatia.
H.F. Löhr, J.F. Schlaak, A.W. Lohse, W.O. Böcher, S. Kanzler, M. Ibe, P.R. Galle (2000). How long to treat
chronic hepatitis B virus infection with lamivudine? J.Hepatol. 33[2], 343. (Leserbrief)
Stand August 2015Originalarbeiten
J. F. Schlaak, E. Hermann, M. Ringhoffer, P. Probst, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer
(1992): Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur.
J. Immunol. 22, 2771-2776. IF: 4,518
J. F. Schlaak, H. Löhr, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1993): Analysis of the in vitro
cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94, 168-
173. IF: 3,278
J. F. Schlaak, E. Hermann, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Differential effects of
IL-10 on proliferation and cytokine production of human γ/δ and α/β T cells. Scand. J. Immunol. 39, 209-215. IF:
1,882
J. F. Schlaak, E. Schmitt, C. Hüls, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): A sensitive and specific
bioassay for the detection of human interleukin-10. J. Immunol. Methods. 168, 49-54. IF: 2,005
J. F. Schlaak, P. Nieder, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Human T helper cells reactive with
somatic bacterial antigens belong to the Th1 subset. Med. Microbiol. Immunol. 183, 169-175. IF: 2,433
J. F. Schlaak, M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K.-H. Meyer zum Büschenfelde, B.
Fleischer (1994): T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102[2], 145-
149. IF: 6,372
H. F. Löhr, J. F. Schlaak, G. Gerken, B. Fleischer, H.-P. Dienes, K.-H. Meyer zum Büschenfelde (1994):
Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients
with chronic hepatitis of different etiology. Liver. 14, 161-166. IF: 4,412
C. Claus, J. F. Schlaak, M. Dittmayer, K.-H. Meyer zum Büschenfelde, W. Dippold. Inhibition of antibody-induced
proliferation of human CD8+ T cells by CD16+ natural killer cells (1994): Eur. J. Immunol. 24, 1208-1212. IF: 4,518
J. F. Schlaak, A. Schwarting, P. Knolle, K.-H. Meyer zum Büschenfelde, W. Mayet (1995): Effects of Th1 and Th2
cytokines on cytokine production and ICAM-1 expressionon synovial fibroblasts. Ann. Rheum. Dis. 54[7], 560-
565. IF: 8,727
J. F. Schlaak, C. Clauss, K.-H. Meyer zum Büschenfelde, W. Dippold (1995): Anti-GD3 antibodies are potent
activators of human γ/δ and α/β positive T cells. Scand. J. Immunol. 41[5], 474-480. IF: 1,882
P. Knolle, J. F. Schlaak, A. Uhrig, P. Kempf, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Human Kupffer
cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22[2], 226-229. IF: 10,401
H. F. Löhr, J. F. Schlaak, H. P. Dienes, J. Lorenz, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Liver
cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.
Digestion. 56[1], 41-45. IF: 2,032
M. Girndt, H. Köhler, E. Schiedhelm-Weick, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, B. Fleischer (1995):
Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune
defect in chronic hemodialysis patients. Kidney Int. 47[2], 559-565. IF: 8,520
H. F. Löhr, W. Weber, J. F. Schlaak, B. Goergen, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Proliferative
response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus
hepatitis B virus mutants. Hepatology. 22[1], 61-68. IF: 11,190
H. F. Löhr, J. F. Schlaak, G. Kollmannsperger, H.-P. Dienes, K.-H. Meyer zum Büschenfelde, G. Gerken (1996):
Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and
functional significance. Liver. 16, 174-182. IF: 4,412
J. F. Schlaak, I. Pfers, K.-H. Meyer zum Büschenfelde, E. Märker-Hermann (1996): Different cytokine profiles in
the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin.
Exp. Rheumatol. 14, 155-162. IF: 2,973
G. Zissel, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Regulation of cytokine release by alveolar
macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta. Eur. Cytokine Netw.
7[1], 59-66. IF : 1,800
M. Heike, J. F. Schlaak, H. Schulze-Bergkamen, S. Heyl, W. Herr, U. Schmitt, P. M. Schneider, K.-H. Meyer zum
Büschenfelde (1996): Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human
sarcoma: evidence for several recognized antigens. J. Immunol. 156[6], 2205-2213. IF: 5,362
A. Schwarting, J. F. Schlaak, J. Lotz, I. Pfers, K.-H. Meyer zum Büschenfelde, W. Mayet (1996): Endothelin-1
modulates the expression of adhesion molecules on synovial fibroblast-like synovial cell (FLS). Scand. J.
Rheumatol. 25, 246-256. IF: 2,607
G. Zissel, J. Homolka, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Anti-inflammatory cytokine release
by alveolar macrophages in pulmonary sarcoidosis. Am. J. Resp. Crit. Care Med. 154, 713-719. IF: 11,986
H. F. Löhr, J. F. Schlaak, A. W. Lohse, W. O. Böcher, M. Arenz, G. Gerken, K.-H. Meyer zum Büschenfelde
(1996): Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive
autoimmune hepatitis. Hepatology. 24, 1416-1421. IF: 11,190
M. Heike, J. F. Schlaak, S. Heyl, H. Schulze-Bergkamen, U. Schmitt, K.-H. Meyer zum Büschenfelde (1997):
Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells. Scand. J.
Immunol. 45[2], 221-226. IF: 1,882
A. Schwarting, J. F. Schlaak, E. Wandel, K.-H. Meyer zum Büschenfelde, W. Mayet (1997): Human renal tubular
epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol. Dial. Transplant. 12[5], 916-923.
IF: 3,488
J. F. Schlaak, M. Trippler, I. Ernst, K.-H. Meyer zum Büschenfelde, G. Gerken (1997): Chronic hepatitis C: The
viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy. J.
Hepatol. 27[5], 917-921. IF: 10,401
K. Barbulescu, C. Becker, J. F. Schlaak, E. Schmitt, K.-H. Meyer zum Büschenfelde (1998): Cutting edge: IL-12
and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4+ T
lymphocytes. J. Immunol. 160[8], 3642-3647. IF: 5,362
J. F. Schlaak, T. Pitz, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1998): IL-12 enhances deficient
HCV-antigen induced Th1-type immune response of peripheral blood mononuclear cells. J. Med. Virol. 56, 112-
117. IF: 2,217
H. F. Löhr, S. Krug, W. Herr, S. Weyer, J. F. Schlaak, T. Wölfel, G. Gerken, K.-H. Meyer zum Büschenfelde
(1998): Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic
hepatitis B. Liver. 18, 405-413. IF: 4,412
K. Hildner, E. Märker-Hermann, J. F. Schlaak, C. Becker, T. Germann, E. Schmitt, K.-H. Meyer zum
Büschenfelde, M. F. Neurath (1998): Azathioprine, mycophenolate mofetil and methotrexate specifically modulate
cytokine production by T cells. Ann. New York Acad. Sci. USA. 859, 204-207. IF: 3,155
M. F. Neurath, R. Wanitschke, M. Peters, K. Hildner, R. Tufan, K.-H. Meyer zum Büschenfelde, J. F. Schlaak
(1998). Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological
studies. Ann. New York Acad. Sci. USA. 859, 315-318. IF: 3,155
H. F. Löhr, G. Gerken, M. Roth, S. Weyer, J. F. Schlaak, K.-H. Meyer zum Büschenfelde (1998): The cellular
immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may
determine the therapy outcome. J. Hepatol. 29[4], 524-532. IF: 10,401
W. O. Böcher, S. Herzog-Hauff, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, H. F. Löhr (1999): Kinetics of
hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination:
stimulation of the in vitro antibody response by interferon gamma. Hepatology. 29[1], 238-244. IF: 11,190
M. F. Neurath, K. Hildner, C. Becker, J. F. Schlaak, K. Barbulescu, T. Germann, E. Schmitt, P. Schirmacher, S.
Haralambous, M. Pasparakis, G. Kollias, E. Märker-Hermann (1999): Methotrexate specifically modulates
cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for
methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115[1], 42-55. IF: 3,278
J. F. Schlaak, G. Tully, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): HBV-specific immune defect
in chronic hepatitis B is correlated with a dysregulation of pro- and antiinflammatory cytokines. Clin. Exp.
Immunol. 115, 508-514. IF: 3,278
M. F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (1999):
Randomised trial of mycophenolate mofetil for treatment of chronic active Crohn´s disease. Gut. 44[5], 625-628.
IF: 13,319
J. F. Schlaak, G. Tully, H. F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): The presence of high
amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBVinduced
immune response. J. Hepatol. 30, 353-358. IF: 10,401
K. Hildner, S. Finotto, C. Becker, J. F. Schlaak, P. Schirmacher, P. R. Galle, E. Märker-Hermann, M. F. Neurath
(1999): Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose
methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137-146. IF: 3,278
W. J. Mayet, A. Schwarting, A. P. Barreiros, J. F. Schlaak, M. F. Neurath (1999): Anti-PR-3 antibodies induce
endothelial IL-8 release. Eur. J. Clin. Invest. 29, 973-979. IF: 2,834
W. J. Mayet, E. Märker-Hermann, J. F. Schlaak, K.-H.Meyer zum Büschenfelde (1999): Irregular cytokine pattern
of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener’s granulomatosis. Scand.
J. Immunol. 49[6], 585-594. IF: 1,882
A. P. Barreiros, P. Schirmacher, R. Laufenberg-Feldmann, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (2000):
The early immune response in the liver of BALB/c mice infected with S. typhimurium. Scand. J. Immunol. 51[5],
472-478. IF: 1,882
T. Orth, M. Peters, J. F. Schlaak, F. Krummenauer, R. Wanitschke, W. J. Mayet, P. R. Galle, M. F. Neurath
(2000): Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month
pilot study. Am. J. Gastroenterol. 98[5]: 1201-1207. IF: 9,213
R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker,
D. Strand, J. Czaja, J. F. Schlaak, H. A. Lehr, F. Autschbach, G. Schurmann, N. Nishimoto, K. Yoshizaki, H. Ito,
T. Kishimoto, P. R. Galle, S. Rose-John, M. F. Neurath (2000): Blockade of interleukin 6 transsignaling
suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and
experimental colitis in vivo. Nat. Med. 6[5], 583-588. IF: 28,054
P. Micke, K. M. Beeh, J. F. Schlaak, R.Buhl (2001). Oral supplementation with whey proteins increases plasma
glutathione levels of HIV-infected patients. Eur. J. Clin. Invest 31[2], 171-178. IF: 2,834
B. Strobl, V. Arulampalam, H. Is’harc, S. J. Newman, J. F. Schlaak, D. Watling, A.P.Costa-Pereira, F. Schaper, I.
Behrmann, K. C. Sheehan, R. D. Schreiber, F. Horn, P. C. Heinrich, I. M. Kerr (2001). A completely foreign
receptor can mediate an interferon-gamma-like response. EMBO J. 20[19], 5431-5442. IF: 10,748
J.F. Schlaak, A.P. Barreiros, S. Pettersson, P. Schirmacher, K.H. Meyer zum Büschenfelde, M.F. Neurath (2001).
Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septic shock
induced by S. typhimurium in mice. Scand. J. Immunol. 54[4], 396-403. IF: 1,882
F. Aberger, A. P. Costa-Pereira, J. F. Schlaak, T. M. Williams, R. F. O’Shaughnessy, G. Hollaus, I. M. Kerr, A. M.
Frischauf (2001). Analysis of Gene Expression Using High-Density and IFN-gamma-Specific Low-Density cDNA
Arrays. Genomics 77[1/2], 50-57. IF: 2,793
J. F. Schlaak, C. Schramm, K. Radecke, K.-H. Meyer zum Büschenfelde, G. Gerken. Sustained suppression of
HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/Hepatitis C coinfection
(2002). J. Acquir. Immune. Defic. Syndr. 29[2], 145-148. IF: 4,425
A. P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is’harc, I. Gesualdo, S. J. Newman, I. M.
Kerr, V. Poli. Mutational switch of an IL-6 response to an interferon-gamma -like response (2002). P. Natl. Acad.
Sci. USA 99[12], 8043-8047. IF: 9,809
J.F. Schlaak, C.M.U. Hilkens, A.P. Costa-Pereira, B. Strobl, F. Aberger, A.M. Frischauf, I.M. Kerr (2002). Cell-type
and donor-specific transcriptional responses to interferon-alpha – use of customised gene arrays. J. Biol. Chem.
277[51], 49428-37. IF: 4,600
A.P. Barreiros, J.F. Schlaak, G. Gerken, P.R. Galle, H.F. Löhr. Interleukin-2 has no additional therapeutic efficacy
in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin
(2003). Eur. J. Clin. Invest. 33(7):628-9. IF: 2,834
L. Strahle, D. Garcin, P. Le Mercier, J.F. Schlaak, D. Kolakofsky. Sendai virus targets inflammatory responses, as
well as the interferon-induced antiviral state, in a multifaceted manner (2003). J. Virol. 77(14):7903-13. IF: 4,648
C.M.U. Hilkens, J.F. Schlaak, I.M. Kerr. Differential Responses to IFN-alpha Subtypes in Human T Cells and
Dendritic Cells (2003). J. Immunol. 171(10):5255-63. IF: 5,362
A. Luik, S. Knapp, M. Thursz, H.C. Thomas, J.F. Schlaak. Autoregulatory role of Interleukin-10 in hepatitis C
patients treated with IFN-± (2004). J. Interf. Cytok. Res. 24(10): 585-593. IF: 3,899
M. Jones, A. Davidson, L. Hibbert, P. Grünewald, J.F. Schlaak, S. Ball, G.R. Foster, M. Jacobs. Dengue virus
inhibits alpha interferon signaling by reducing STAT2 expression (2005). J. Virol. 79(9):5414-20. IF: 4,648
T. Zoepf, E.J. Maldonado-Lopez, P. Hilgard, A. Dechene, M. Malago, C.E. Broelsch, J. F. Schlaak, G. Gerken. Diagnosis of
biliary strictures after liver transplantation: Which is the best tool? (2005). World J. Gastroenterol. 11(19):2945-8.
IF: 2,433
S. Guan, H. Liu, D. Yang, M. Lu, M. Roggendorf, J. F. Schlaak. Establishment of a new low-density cDNA macroarray
and the application in the activity of IFN against HBV (2005). Chin J Exp Clin Virol. 19(3):236-9.
T. Zoepf, E. Maldonado-Lopez, P. Hilgard, J. F. Schlaak, M. Malago, C.E. Broelsch, U. Treichel, G. Gerken. Endoscopic
therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation (2005). Clin.
Gastroenterol. Hepatol. 3(11):1144-9. IF: 6,543
Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Quality of Life and Psychiatric Complications after Adult Living Donor Liver Transplantation (2006). Liver
Transpl., 12(12):1782-90. IF: 3,793
S. Guan, M. Lu, P. Grünewald, M. Roggendorf, G. Gerken, J. F. Schlaak. The interferon-alpha response in HBVtransfected
HepG2.2.15 cells is partially restored by lamivudine treatment (2007). World J. Gastroenterol., 13(2):
234-241. IF: 2,433
M. Bockhorn, A. Frilling, T. Benkö, J. Best, S.-Y. Sheu, M. Trippler, J. F. Schlaak, Broelsch CE. Tri-iodothyronine
as a stimulator of liver regeneration after partial and subtotal hepatectomy (2007). Eur. Surg. Res., 39(1):58-63.
IF: 1,431
M. Bockhorn, S. Schöllmann, B. Opitz, G.C. Sotiropoulos, S.-Y. Sheu, E. Niehues, M. Trippler, A. Frilling, C.E.
Broelsch, J. F. Schlaak. VEGF does not improve liver regeneration and survival after 90% subtotal liver resection
(2007), Hepatol. Res., 37(5):353-9. IF: 2,218
M. Bockhorn, M. Goralski, D. Prokofiev, P. Dammann, P. Grünewald, M. Trippler, M. Kamler, A. Frilling, C. E.
Broelsch, J. F. Schlaak. VEGF is important for early liver regeneration after partial hepatectomy (2007). J. Surg.
Res., 138(2):291-9. IF: 2,121
J. Wu, M. Lu, Z. Meng, M. Trippler, M. Roggendorf, G. Gerken, J. F. Schlaak. TLR-mediated control of HBV
replication by non-parenchymal liver cells in mice (2007). Hepatology, 46(6):1769-1778. IF: 11,190
M. Bockhorn, T. Benkö, B. Opitz, S.-Y. Sheu, G. C. Sotiropoulos, J. F. Schlaak, C. E. Broelsch, H. Lang. Impact of
hepatic vein deprivation on liver regeneration and function after major hepatectomy (2008). Langenbeck Arch.
Surg., 393(4):527-33. IF: 2,160
Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Selection of donors for adult living-donor liver donation: results of the assessment of the first 205 donor
candidates (2008). Psychosomatics, 49(2):143-51. IF: 1,669
R. Broering, J. Wu, Z. Meng, P. Hilgard, M. Lu, M. Trippler, A. Szczeponek, G. Gerken, J. F. Schlaak. TLR
stimulated non-parenchymal liver cells are potent suppressors of HCV replication (2008). J. Hepatol., 48(6):914-
22. IF: 10,401
M. Bockhorn, C. D. Fingas, Y. Gu, U. Rauen, E. Niehues, A. Frilling, C. E. Broelsch, J. F. Schlaak. Erythropoietin
improves liver regeneration and survival in rat models of extended liver resection and living donor liver
transplantation (2008). Transplantation, 86(11):1578-85. IF: 3,535
J.-P. Sowa, J. Best, T. Benko, M. Bockhorn, Y. Gu, A. Bucchi, G. Gerken, U. Rauen, J. F. Schlaak. The extent of
liver resection modulates the activation of transcription factors and the production cytokines that are involved in
liver regeneration (2008). World. J. Gastroenterol., 14(46):7093-100. IF: 2,433
Z. Meng, S. Qiu, X. Zhang, J. Wu, T. Schreiter, Y. Xu, D. Yang, M. Roggendorf, J. F. Schlaak, M. Lu. Inhibition of
woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene
expression (2009). Virology, 384(1):88-96. IF: 3,278
J. Wu, Z. Meng, J. Min, R. Pei, M. Trippler, R. Broering, A. Bucchi, J.-P. Sowa, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. HBV suppresses Toll-like receptor mediated innate immune
responses in murine parenchymal and non-parenchymal liver cells (2009). Hepatology, 49(4):1132-40. IF: 11,190
B. Wang, M. Trippler, M. Lu, R. Broering, G. Gerken, J. F. Schlaak. Toll-like receptor activated human and murine
hepatic stellate cells are potent regulators of hepatitis C virus replication (2009). J. Hepatol. 2009;51(6):1037-45.
IF: 10,401
X. Zhang, Z. Meng, S. Qiu, Y. Xu, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Lipopolysaccharide induced
innate immune responses in primary hepatocytes inhibit woodchuck hepatitis virus replication via interferonindependent
pathways (2009). Cell. Microbiol. 11(11):1624-37. IF: 4,816
M.R. Rani, Y. Xu, J. C. Lee, J. Shrock, A. Josyula, J. F. Schlaak, S. Chakraborthy, N. Ja, R.M. Ransohoff, R. A.
Rudick. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta (2009). Ann. N. Y. Acad.
Sci. 1182:58-68. IF: 3,155
J. Wu, Z. Meng, M. Jiang, E. Zhang, M. Trippler, R. Broering, A. Bucchi, F. Krux, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. TLR induced innate immune response in non-parenchymal liver
cells are cell type-specific (2010). Immunology. 129 (3), 363-374. IF: 3,735
Y. Erim, S. Tagay, M. Beckmann, S. Bein, V. Cicinatti, S. Beckebaum, W. Senf, J. F. Schlaak. Depression and
Protective Factors of Mental Health in People with Hepatitis C: a questionnaire survey (2010). Int. J. Nurs. Stud.
47(3):342-349. IF: 2,248
T. Benkö, S. Frede, Y. Gu, J. Best, H.A. Baba, J. F. Schlaak, H. de Groot, J. Fandrey, U. Rauen. Glycine
pretreatment ameliorates liver injury after partial hepatectomy in the rat (2010). J. Invest. Surg., 23(1):12-20. IF:
1,191
R. Broering, M. Trippler, M. Jiang, M. Lu, G. Gerken, J. F. Schlaak. The interferon stimulated gene 15 functions
as a proviral factor for the hepatitis C virus and as an attenuator of the IFN response in hepatocytes (2010). Gut,
59(8):1111-9. IF: 13,319
P. Burbelo, J. Kovacs, K. Ching, A. Issa, M. Iadarola, J. F. Schlaak, H. Masur, M. Polis, S. Kottilil. Proteome-wide
anti-HCV and anti-HIV antibody profiling for predicting and monitoring response to HCV treatment in HIV coinfected
patients (2010). J. Infect. Dis., 15;202(6):894-8. IF: 5,778
J. Ertle, A. Dechêne, J.-P. Sowa, V. Penndorf, K. Herzer, G. Kaiser, J. F. Schlaak, G. Gerken, W.-K. Syn, A.
Canbay. Nonalcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis (2011). Int. J.
Cancer. 1;128(10):2436-43. IF: 5,007
X. Zhang, Z. Ma, E. Zhang, M. Jiang, J. F. Schlaak, M. Roggendorf, M. Lu. Modulation of HBV replication and
hepatocyte differentiation by MicroRNA-1 (2011). Hepatology, 53(5):1476-85. IF: 11,190
A. Katsounas, M. Trippler, S. Bein, S. Kottilil, R. A. Lempicki, G. Gerken, J. F. Schlaak. Altered Expression of
SHIP, a Toll-like Receptor 2 and 4 Pathway Inhibitor, is Associated with the Severity of Liver Fibrosis in Chronic
Hepatitis C Virus Infection (2011). J. Infect. Dis., 204(8):1181-5. IF: 5,778
M. Montag, R. Broering, J. Min, M. Lu, J.-P. Sowa, G. Gerken, J. F. Schlaak. Corticosteroids shift the response
pattern of the hepatic innate immune system from an inflammatory to an anti-inflammatory state (2011). Int.
Immunol., 23(9):537-44. IF: 3,181
T.C. Lauenstein, T.A. Heusner, M. Hamami, J. Ertle, J. F. Schlaak, G. Gerken, A. Bockisch, G. Antoch.
Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries (2011). Rofo,
183(11):1058-1064. IF: 1,961
J. Wu, M.F. Chen, Y.C. Xia, Y. Guo, Y. Lin, C. Sun, C.Y. Zhang, Y. Chen, S.P. Liu, Y.H. Hao, M. Lu, J.F.
Schlaak., D.L. Yang. Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and
its control of HBV replication (2011). Chin. J. of Hepatol., 19(11):838-42.
A. Katsounas, M. Trippler, B. Wang, M. Polis, R. A. Lempicki, S. Kottilil, G. Gerken, J. F. Schlaak. CCL5 is a
marker for early fibrosis in chronic hepatitis C and is regulated by Toll-like receptor 3 signaling and interferon-±
therapy (2012). J. Viral Hep., 19(2):128-37. IF: 3,307
S. Naggie, A. Osinusi, A. Katsounas, E. Hermann, R. Lempicki, J.F. Schlaak, A. Thompson, P. Clark, M. Trippler,
K. Patel, B. Shivakumar, A. Muir, J. McHutchison, D. Goldstein, H. Masur, M. A. Polis, S. Kottilil. Dysregulation
Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With
Depressed Viral Kinetics And Therapeutic Response (2012). Hepatology. 56(2):444-54. IF: 11,190
A. Osinusi, S. Naggie, S. Poonia, M. Trippler, Z. Hu, J. F. Schlaak, D. Fishbein, H. Masur, M. Polis, S. Kottilil.
ITPA Gene Polymorphisms Significantly Affect Hemoglobin Decline and Treatment Outcomes in HIV/HCV Coinfected
Patients (2012). J. Med. Virol., 84(7):1106-14. IF: 2,217
A. Katsounas, M. Trippler, S. Kottilil, R. A. Lempicki, C. H. Lane, G. Gerken, J. F. Schlaak. Cytokine/Chemokine
patterns connect various host and viral characteristics with clinics during chronic hepatitis C (2012). Eur. J. Med.
Res., 11;17(1):9. IF: 1,398
J. Theysohn, J. F. Schlaak, S. Müller, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective internal
radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after Sorafenib
administration (2012). J. Vasc. Int. Radiol., 23(7):949-52. IF: 2,149
X. Zhang, Z. Ma, H. Liu, J. Liu, Z. Meng, R. Broering, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Role of Tolllike
receptor 2 in the immune response against Hepadnaviral infection (2012). J. Hepatol., 57(3):522-8. IF: 10,401
J. F. Schlaak, M. Trippler, Y. Erim, B. Kis, B. Wang, N. Scherbaum, G. Gerken. Common pathways in
endogenous depression and depression induced by IFN-± therapy for chronic hepatitis C (2012). PLoS One,
7(6):e38668. IF: 3,534
G. Ren, S. Esser, C. Jochum, J. F. Schlaak, G. Gerken, D. Schadendorf, U. Dittmer, G. Wu, Z. Yuan, J. Timm. IL21
augments the HBV-specific CD8+T cell response in vitro in patients coinfected with HIV-1 (2012). AIDS,
26(17):2145-53. IF: 6,557
J. M. Theysohn, S. Müller, J. F. Schlaak, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective
Internal Radiation Therapy (SIRT) of hepatic tumors: how to deal with the cystic artery (2012). Cardiovasc
Intervent Radiol., 36(4):1015-22. IF: 1,965
J. M. Ertle, D. Heider, M. Wichert, B. Keller, R. Kueper, P. Hilgard, G. Gerken, J. F. Schlaak. Combination of
Alphafetoprotein and Des-Gamma-Carboxy Prothrombin is superior in detection of Hepatocellular Carcinoma
(2013). Digestion, 87:121-131. IF: 2,032
A. Katsounas, J. J. Hubbard, C. H. Wang, X. Zhang, D. Dou, B. Shivakumar, S. Winter, J. F. Schlaak, R. A.
Lempicki, H. Masur, M. Polis, S. Kottilil, A. Osinusi. High Interferon Stimulated Gene ISG-15 Expression Affects
HCV Treatment Outcome in HIV/HCV Coinfected Patients (2013). J. Med. Virol., 85(6):959-63. IF: 2,217
M. Schuchmann, J.M. Kittner, J. F. Schlaak, D. Klass, N. Dikopolous, C. Eisenbach, T. Berg, C. Trautwein, R.
Günther, S. Zeuzem, R. Gösseringer, A. Ehrlich, K. Neumann, D. Wachtlin, M.F. Sprinzl, T. Zimmermann, W.O.
Böcher, P.R. Galle. Viral efficacy and safety of all-trans retinoic acid in HCV patients with previous non-response
(2013). Digest. Liver. Dis., 45(4):323-9. IF: 2,889
F. A. Tucci, R. Bröring, P. Johansson, J. F. Schlaak, R. Küppers. B cells in chronically hepatitis C virus-infected
individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes (2013). J. Virol.,
87(5):2956-62. IF: 4,648
D. A. Megger, T. Bracht, M. Kohl, M. Ahrens, F. Weber, A.-C. Hoffmann, C. Stephan, M. Eisenacher, J. F.
Schlaak, H. A. Baba, H. E. Meyer, B. Sitek. Combining different quantification techniques in proteomics-based
clinical studies reveals confident hepatocellular carcinoma biomarker candidates (2013). Mol. Cell. Proteomics,
12(7):2006-20. IF: 7,254
Kohl M, Megger DA, Trippler M, Meckel H, Ahrens M, Bracht T, Weber F, Hoffmann AC, Baba HA, Sitek B,
Schlaak JF, Meyer HE, Stephan C, Eisenacher M. A practical data processing workflow for multi – OMICS
projects (2013). Biochim Biophys Acta. doi:pii: S1570-9639(13)00092-7. 10.1016/j.bbapap.2013.02.029. IF: 3,191
I. Nel, H. A. Baba, J. Ertle, F. Weber, B. Sitek, M. Eisenacher, H. E. Meyer, J. F. Schlaak, A.-C. Hoffmann.
Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular
carcinoma (2013). Translat. Oncol., 6(4):420-8. IF: 2,558
R. Pei, B. Qin, X. Zhang, W. Zhu, T. Kemper, Z. Ma, M. Trippler, J. F. Schlaak, X. Chen, M. Lu. Interferon-induced
protein with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication (2013). J.
Innate Immun., in press. IF: 4,557
R. Broering, C. I. Real, K. Jahn-Hofmann, L. Ickenstein, M. John, M. Lutterbeck, K. Kleinehr, G. Gerken, J. F.
Schlaak. Chemical modifications on siRNAs avoid the Toll-like receptor-mediated activation of the hepatic
immune system in vivo and in vitro (2013). Int. Immunol., in press. IF: 3,181
R. Broering, M. Lutterbeck, K. Kleinehr, M. Trippler, L. Poggenpohl, A. Paul, G. Gerken, J. F. Schlaak. Longterm
stimulation of toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses
induced by poly I:C treatment (2013). J. Viral Hep., in press. IF: 3,307
M. Jiang, R. Broering, M. Trippler, L. Poggenpohl, G. Gerken, M. Lu, J. F. Schlaak. Toll-like receptor-mediated
immune responses are attenuated in the presence of the hepatitis B virus surface antigen (2013). J. Viral Hep., in
press. IF: 3,307
Z. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. Choi
criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for
hepatocellular carcinoma (2013). Oncol. Lett., 6: 1707-1712, 2013. IF: 0,987
C. Real, D. Megger, B. Sitek, K. Jahn-Hofmann, L. Ickenstein, M. John, K. Kuhlmann, M. Eisenacher, H. E.
Meyer, G. Gerken, R. Broering, J. F. Schlaak. Identification of Proteins that Mediate the Pro-viral Functions of the
Interferon Sensitive Gene 15 in Hepatitis C Virus Replication (2013). Antivir. Res., 100(3):654-61. IF: 3,434
Y. Gu, J.-P. Sowa, S. Zhang, A. Paul, G. Gerken, J. F. Schlaak. VEGF improves liver regeneration and survival
after 90% hepatectomy in a rat model of diet-induced steatosis (2013). Digestion, 22;88(4):235-242. IF: 2,032
Z. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. A new
model to estimate prognosis after Yttrium-90 radioembolization in patients with hepatocellular carcinoma (2013).
PLoS One, 8(12):e82225. doi: 10.1371/journal.pone.0082225. IF: 3,534
C. Hoyo-Becerra, A. Huebener, M. Trippler, M. Lutterbeck, Z. Liu, K. Truebner, T. Bajanowski, G. Gerken, D.M.
Hermann, J. F. Schlaak. Concomitant interferon alpha stimulation and TLR3 activation induces neuronal
expression of depression-related genes that are elevated in the brain of suicidal persons (2013). PLoS One,
8(12):e83149. IF: 3,534
P. Hilgard, A. Dechene, A. Canbay, K. Herzer, J. F. Schlaak, U. Treichel, A. Gassel, H. Baba, T. Zoepf.
Diagnostic Mini-Laparoscopy in hepatic diseases and primary liver- and bile duct cancer: An over 10-year
experience in 1788 cases (2014). Digestion, 89(2):156-164. IF: 2,032
J. Liu, M. Jiang, Z. Ma, K. Dietze, G. Zelinskyy, D. Yang, U. Dittmer, J. F. Schlaak, M. Roggendorf, M. Lu.
Stimulation of Mouse Liver Endothelial Cells by Toll-Like Receptor 1/2 Ligands shifts T cell suppression to antiviral
T cell immunity (2013). J. Immunol., 191(12):6178-90. IF: 5,362
J. Theysohn, J. Ertle, S. Müller, J. F. Schlaak, F. Nensa, S. Sipillae, A. Bockisch, T. C. Lauenstein. Hepatic
volume changes after lobar Selective Internal Radiation Therapy (SIRT) of hepatocellular carcinoma (2013). Clin.
Radiol. doi:pii: S0009-9260(13)00457-1. 10.1016/j.crad.2013.09.009. IF: 1,663
M. Jiang, R. Broering, M. Trippler, J. Wu, E. Zhang, X. Zhang, G. Gerken, M. Lu, J. F. Schlaak. MicroRNA-155
controls toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver (2014). J. Viral Hep.,
21(2):99-110. IF: 3,307
J. Schelhorn, J. Theysohn, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal
Radiation Therapy of Hepatic Tumors: is coiling of the gastroduodenal artery always beneficial (2014)? Clin.
Radiol., in press. IF: 1,663
A. Baraniskin, S. Nöpel-Dünnebacke, C. Gerges, T. Bracht, B. Sitek, H. E. Meyer, J. F. Schlaak, J. Ertle, R.
Schroers, C. Pox, W. Schmiegel, S. A. Hahn. Analysis of U2 small nuclear RNA fragments in the bile
differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders (2014).
Dig. Dis. Sci., in press. IF: 2,550
F. A. Tucci, R. Broering, M. Lutterbeck, J. F. Schlaak, R. Küppers. Intrahepatic B cell follicles of chronically
hepatitis C virus-infected individuals lack signs of an ectopic germinal center reaction (2014). Eur. J. Immunol., in
press. IF: 4,518
A. Katsounas, J. J. Rasimas, M. A. Polis, G. Guido, J. F Schlaak, R. A Lempicki, D. L. Rosenstein, S. Kottilil.
Interferon Stimulated Gene ISG20 links psychiatric events to distinct Hepatitis C Virus responses in HIV patients
(2014). J. Med. Virol., IF: 2,217
C. Thöns, C. Berger, M. Trippler, H. Siemann, M. Lutterbeck, R. Bröring, J. F. Schlaak, F. M. Heinemann, P.A.
Horn, J. Nattermann, N. Scherbaum, G. Alter, J. Timm. KIR2DL3+NKG2A- Natural Killer Cells are Associated with
Protection from Productive Hepatitis C Virus Infection in People who Inject Drugs (2014). J. Hepatol., IF: 10,401.
J. Wu, M. Chen, Y. Lin, Y. Xia, C. Sun, J. Wang, Y. Guo, J. Song, E. Zhang, B. Wang, X. Zhen, J. F. Schlaak, M.
Lu, D. Yang. Polyinosinic-polycytidylic acid treatment leads to the Interferon-dependent clearance of hepatitis B
virus in a hydrodynamic injection mouse model (2014). J. Virol., IF: 4,648
El Fouly, J. Ertle, A. El Dorry, M. Shaker, H. Abdella, S. Mueller, E. Barakat, T. Lauenstein, A. Bockisch, G.
Gerken, J. F. Schlaak. Intermediate Stage Hepatocellular Carcinoma: Radioembolization with Yttrium 90 or
Chemoembolization (2014)? Liver Int., 4,412.
J. Padden, D. A. Megger, T. Bracht, H. Reis, M. Kohl, M. Eisenacher, J. F. Schlaak, A. E. Canbay, F. Weber, A.-
C. Hoffmann, K. Kuhlmann, H. E. Meyer, H. A. Baba, B. Sitek. Identification of novel biomarker candidates for the
immunohistochemical diagnosis of cholangiocellular carcinoma (2014). Mol. Cell. Proteomics, in press. IF: 7,254
C. Hoyo-Becerra, Z. Liu, J. Yao, B. Kaltwasser, D. M. Hermann, J. F. Schlaak. Rapid regulation of depressionassociated
genes in a new mouse model mimicking interferon-±-related depression in hepatitis C virus infection
(2014). Mol. Neurobiol., in press. IF: 5,286
I. Nel, H.A. Baba, F. Weber, B. Sitek, M. Eisenacher, H.E. Meyer, J.F. Schlaak, A.C. Hoffmann. IGFBP1 in
epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular
carcinoma (2014). Biomark Med. 8(5):687-98. IF: 2,858
J. Schelhorn, T. Schlosser, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal
Radiation Therapy of Hepatic Tumors: Procedural implications of a patent hepatic falciform artery (2014).
Springerplus. 3:595.
H. Reis, C. Pütter, D. A. Megger, T. Bracht, F. Weber, A.-C. Hoffmann, J. Wohlschlaeger, S. Hagemann, M.
Eisenacher, A. Scherag, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. A structured proteomic
approach identifies 14-3-3Sigma as a novel and reliable diagnostic protein biomarker in liver tumours. BBA – Prot.
Proteom., in press. IF: 3,191
Z. Zhang, J. Xia, B. Sun, Y. Dai, X. Li, J. F. Schlaak, M. Lu. In vitro and in vivo replication of a chemically
synthesized consensus genome of hepatitis B virus genotype B (2015). J Virol Methods. pii: 213:57-64. IF: 1,883
T. Bracht, V. Schweinsberg, M. Trippler, M. Kohl, M. Ahrens, J. Padden, W. Naboulsi, D. A. Megger, M.
Eisenacher, C. H. Borchers, J. F. Schlaak, C.-A. Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B. Sitek.
Quantitative proteomics reveal the expression of fibulin-5 in association with hepatic fibrosis (2015). J. Proteome
Res., in press.
H. Reis, J. Padden, M. Ahrens, C. Pütter, S. Bertram, L. Pott, A.-C. Reis, F. Weber, B. Juntermanns, A.-C.
Hoffmann, M. Eisenacher, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. Differential proteomic and
tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid
carcinomas. Pathology, in press.
Eingereichte Publikationen:
M. A. Guzzardi, N. Habib, D. Kitsberg, K. Uygun, M. Trippler, J. F. Schlaak, J. Timm, N. Friedman, Y. Nahmi.
Transcriptional-Metabolic Reprogramming of HCV-infection from Primary Human Hepatocytes Co-cultures to
Clinical Samples. Submitted.
S. Hagemann, H. Reis, K. Lorenz, J. Wohlschlaeger, D. Moellmann, B. Sitek, J. F. Schlaak, H. E. Meyer, M.
Eisenacher, D. A. Megger, A.-C. Hoffmann, F. Weber, H. A. Baba. Eukaryotic elongation factor 2 is a
prognostic marker and its kinase activated in hepatocellular carcinoma eEF2 and eEF2-kinase in HCC.
Submitted.
Z. Zhang, Y. Zhang, Q. Su, L. Zhang, J. F. Schlaak, M. Lu, X. Li. Family-based association testing reveals
different roles of IL28B, TLR3, and HLA-DR in hepatitis B virus infection. Submitted.
R. Broering, M. Trippler, M. Lutterbeck, C.I. Real, D.A. Megger, T. Bracht, B. Sitek, K. Kuhlmann, M.
Eisenacher, H.E. Meyer, H.A. Baba, F. Weber, A.C. Hoffmann, G. Gerken, J. F. Schlaak. Proteasome
S. Berhane, H. Toyoda, T. Tada, T. Kumada, C. Kagebayashi, S. Satomura, N. Schweitzer, A. Vogel, M.
P.Manns, J. Benckert, T. Berg, J. Best, A. Dechêne, G. Gerken, J. F Schlaak, A. Weinmann, M. A. Wörns, W.
Yeo, F. Mo, S. L.Chan, H. Reeves, P. Johnson. Serology-based diagnosis and prognostication in HCC:
Application of the GALAD and BALAD-2 models in an international setting. Submitted.
J. Petersen, R. Heyne, S. Mauss, J. F. Schlaak, W. Schiffelholz, C. Eisenbach, H. Hartmann, M. Wiese, K.
Boeker, H.-F. Loehr, C. John, M. Leuschner, C. Trautwein, G. Felten, A. Trein, W. Krause, S. Ruppert, T.
Warger, D. Hueppe. Efficacy and safety of tenofovir disoproxil fumarate treatment in chronic hepatitis B
patients: a 3 year prospective field practice study in Germany. Submitted.
D. A. Megger, K. Rosowski, M. Ahrens, T. Bracht, M. Eisenacher, J. F. Schlaak, F. Weber, A.-C. Hoffmann,
H. E. Meyer, H. A. Baba, B. Sitek. Quantitative proteome analysis of human hepatocellular carcinoma using
tandem mass tags. Submitted.
W. Naboulsi, D. A. Megger, T. Bracht, M. Kohl, M. Turewicz, M. Eisenacher, D. M. Voss, J. F. Schlaak, A.-C.
Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B Sitek. Quantitative proteome analysis of hepatocellular
carcinoma tissue reveals Versican as potential biomarker for early-stage HCC diagnosis. Submitted.
C. I. Real, M. Lu, J. Liu, X. Huang, M. Trippler, M. Hossbach, J. Deckert, K. Jahn-Hofmann, L. M. Ickenstein,
M. J. John, K. Gibbert, U. Dittmer, H.-P. Vornlocher, R. Schirmbeck, G. Gerken, J. F. Schlaak, R. Broering.
The hepatitis B virus (HBV) surface antigen impedes hepadnaviral replicationdependent interferon responses
in a HBV transgenic mouse model. Submitted.
S. Bertram, J. Padden, J. Kaelsch, M. Ahrens, L. Pott, A. Canbay, F. Weber, C. Fingas, A. C Hoffmann, A.
Vietor, J. F Schlaak, M. Eisenacher, H. Reis, B. Sitek, H. A Baba. Immunostaining for SerpinH1, 14-3-3-
Sigma and ki67 may be useful to differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Submitted.
Fallmitteilungen
T. Wölfel, P. Schirmacher, J. F. Schlaak, P. Knolle, H.-P. Dienes, W. Dippold, K.-H. Meyer zum Büschenfelde, G.
Gerken. Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and
advanced human immunodeficiency virus infection (1994). Clin. Investig. 72, 1030-1036.
C. Schramm, J.F. Schlaak, P.R. Galle. Rapid development of Epstein-Barr virus-associated Hodgkin’s disease
after cessation of foscarnet therapy in an HIV-infected patient (2000). Int.J.STD AIDS 11[9], 609-610.
G.C. Sotiropoulos, J. Treckmann, A. Radtke, G. Antoch, E. Brokalaki, J.F. Schlaak, C. E. Broelsch. Arterioportal fistula
complicating endoscopic retrograde cholangiography (2005). Endoscopy 37[1], 93-4.
A. Katsounas, C. Jochum, A. Canbay, J.F. Schlaak, W. Gerlich, G. Gerken. Core Promoter Mutant HBV Non-responding
To Adefovir after Viral Breakthrough on Lamivudine: Rapid Virologic Response to Tenofovir Plus Lamivudine in a
Cirrhotic Patient (2008). Eur J Med Res. 27;13(10):472-5.
A. Abendroth, R. Klein, J.F. Schlaak, K.A. Metz, G.J. Dobos, J. Langhorst. Imposanter Befund einer Melanosis coli
nach jahrzehntelangem Abusus von Anthrachinonderivaten – Ein Risikofaktor für kolorektale Neoplasien (2009)?
Z. Gastroent. 47 (6), 579-82.
M. Buechter, C. G. Klein, C. Kloeters, J.F. Schlaak, A. Canbay, G. Gerken, A. Kahraman. Tacrolimus as a
reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with
IgG4-associated cholangitis (2014). Z Gastroenterol. 52(6):564-568.
Übersichtsarbeiten
P. Knolle, H. Löhr, U. Treichel, H.-P. Dienes, A. Lohse, J. F. Schlaak, G.Gerken (1995): Parenchymal and
nonparenchymal liver cells and their interaction in the local immune response. Z. f. Gastroenterol., 33, 613-
620.
J. F. Schlaak, H. Koehler, G.Gerken (1996): Hepatitis G virus: an old, but newly discovered hepatotropic
virus. Is it of interest for the nephrologist ?. Nephrol.Dial.Transplant. 11[8], 1522-1523.
J. F. Schlaak, G. Gerken (1997): Aktuelle Strategie in der Diagnostik und Therapie der chronischen
Virushepatitiden. Tägl. prax., 38, 515-526.
J. F. Schlaak, G. Gerken (1997): Diagnose und Therapie der chronischen Virushepatitiden. Internist. prax.,
37, 519-530.
J. F. Schlaak (1997): Virushepatitiden – Verlauf und extrahepatische Manifestationen. Krankenhaus Arzt, 70,
8-9.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnostik und Therapie. Fortschr.
Med.115:34-36.
J. F. Schlaak, G. Gerken (1997): G. Chronische Hepatitiden. Differentialdiagnose der Hepatitis C. Fortschr.
Med.115:38-39.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnose der Hepatitis B, D und G.
Fortschr. Med.115:44-46.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Diagnose der autoimmunen Lebererkrankungen.
Fortschr. Med. 115:33-34.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der chronischen Virushepatitiden.
Fortschr. Med. 115:48-50.
J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der autoimmunen Leberkrankungen.
Fortschr. Med. 115:52-53.
J. Wu, R. Bröring, J. F. Schlaak. The role of the innate immune system of the liver in the control of HBV and
HCV (2008). Virologica Sinica 23 (2): 116-123.
J. Ertle, T. Lauenstein, J. F. Schlaak. Benefit of using TARE-Y90 comparing with TACE in the management
of primary and secondary liver tumors (2011). Eur. J. Clin. Med. Oncol., 3(1): 44-50.
A. Katsounas, J. F. Schlaak, R. A. Lempicki. CCL5: A Double-edged Sword in Host Defense against the
Hepatitis C Virus (2011). Int. Rev. Immunol., 30(5-6):366-78. IF: 2,641
R. Broering, M. Lu, J. F. Schlaak. Toll-like receptors in liver health and disease: mechanisms and therapeutic
potential (2011). Clin. Science, 1;121(10):415-26. IF: 4,613
X. Zhang, A. Kraft, R. Broering, J. F. Schlaak, U. Dittmer, M. Lu. Preclinical development of TLR ligands as
drugs for the treatment of chronic viral infections (2012). Exp. Opin. Curr. Drug Disc., 7(7):597-611.
J. Ertle, G. Gerken, J. F. Schlaak. Lokalablative Therapien zur Behandlung des hepatozellulären Karzinoms
(2012). Der Gastroenterologe, in press.
J. Ertle, G. Gerken, J. F. Schlaak. Radioembolisation bei forgeschrittenem hepatozellulären Karzinom.
Viszeralmedizin (2012). Viszeralmed. 28(5), 311-16.
K. Gibbert, J. F. Schlaak, D. L. Yang, U. Dittmer. Interferon alpha subtypes: Distinct Biological activities in
anti-viral therapy (2012). Br. J. Pharm., 168(5):1048-58.
H. Lang, J. Ricke, J.F. Schlaak. Resektion oder interventionelle Therapie beim hepatozellulären Karzinom:
welche Methode für welchen Patienten (2013)? Dtsch Med Wochenschr. 138(36):1780-4.
J. F. Schlaak. Zufallsbefund Leberrundherd: Bösartig oder gutartig (2013)? Der Allgemeinarzt, 11:34-38.
J. F. Schlaak. Labordiagnostik bei primärem Leberzellkarzinom (2014). Der Gastroenterologe, 9:138-144.
I. Nel, P. David, G. Gerken, J. F. Schlaak, A.-C. Hoffmann. Role of circulating tumor cells and cancer stem
cells in hepatocellular carcinoma (2014). Hepatol. Int., 8(3):321-9.
C. Hoyo-Becerra, J. F. Schlaak, D. M. Hermann. Insights from interferon-alpha-related depression for
idiopathic major depression (2014). Brain Behav. Immun., 42:222-31.
J. F. Schlaak. Radioembolisation with yttrium-90 glass microspheres for patients with hepatocellular
carcinoma: a review (2014). Hep. Oncol., 1(4): 387-393.
J. F. Schlaak. The evolving role of radioembolization for the treatment of Hepatocellular carcinoma.
(Submitted)
Buchbeiträge
J. F. Schlaak, G. Gerken (1997): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
J. F. Schlaak, G. Gerken (2001): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
J. F. Schlaak, G. Gerken (2003): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion.
In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
J. F. Schlaak, G. Gerken (2004): Management of IL-2 toxicity. In: Immunotreatment and gene therapy of HIV
infection, Hengge, Kabelitz (Hrsg.), Unimed Verlag, Bremen.
A. Canbay, J. F. Schlaak, G. Gerken, R. Gieseler (2007). Dysregulated Apoptosis in Liver Diseases. In : Cell
apoptosis: Regulation and environmental factors, (Schultz (Hrsg.), Nova Science Publishers, Inc, New York,
USA.
J. F. Schlaak, G. Gerken (2007): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion.
In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
C. Jochum, J.F. Schlaak (2010). Hepatitis C: Symptoms, Diagnosis and Treatment, pp. 135-158 In :
Advances in Medicine and Biology, Vol. 9, (Berhardt (Hrsg.), Nova Science Publishers, Inc, New York, USA.
R. Bröring, M. Lu, J.F. Schlaak (2011). Toll like receptors in chronic viral hepatitis – friend and foe. In: Viral
Hepatitis, ISBN 979-953-307-103-8, InTech, Rijeka, Croatia.
H.F. Löhr, J.F. Schlaak, A.W. Lohse, W.O. Böcher, S. Kanzler, M. Ibe, P.R. Galle (2000). How long to treat
chronic hepatitis B virus infection with lamivudine? J.Hepatol. 33[2], 343. (Leserbrief)
Stand August 2015